

1 Title Page

Clinical Study Report	
Study Title:	A 4-Week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly- dosed, Multicenter Study to Evaluate the Efficacy and Safety of SYM-23 in Acutely Psychotic Adult Subjects With Schizophrenia
Investigational Drug Name:	SYM-23
Indication:	Schizophrenia
Protocol Number:	Doc Compare POC
Drug Development Phase:	2
Study Initiation Date:	
Study Completion Date:	
GCP Statement:	This study was conducted in compliance with the Declaration of Helsinki and Good Clinical Practice or Trials on Medicinal Products, including archiving of essential study documents.
Date of Report:	08-02-2023

Signature pages for clinical study report

I have read this report and confirm that to the best of my knowledge it accurately describes the conduct and results of the study.

Signed:	Date: ____/____/____
Print name:	
Affiliation:	
Address:	
Signed:	Date: ____/____/____
Print name:	
Affiliation:	
Address:	
Signed:	Date: ____/____/____
Print name:	
Affiliation:	
Address:	
Signed:	Date: ____/____/____
Print name:	

Affiliation:	
Address:	
Signed:	Date: ____/____/____
Print name:	
Affiliation:	
Address:	

2 Study Synopsis

Name of Sponsor: XXX Pharmaceuticals, Inc.	INDIVIDUAL STUDY TABLE		(For National Authority Use Only)
Name of Finished Product: N/A	Referring to Module 5 of the Dossier <u>Volume:</u> <u>Page:</u>		
Name of Active Ingredient(s):			
Title of Study	A 4-Week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly- dosed, Multicenter Study to Evaluate the Efficacy and Safety of SYM-23 in Acutely Psychotic Adult Subjects With Schizophrenia		
Investigator(s)			
Study Center(s)	Approximately 35 centers globally		
Publication	N/A		
Study Period	From: To:	Phase: 2	
Objectives	Study Objectives: Primary:		

	<p>To evaluate the efficacy of flexibly dosed SYM-23 (50 or 75 mg/day) compared with placebo in acutely psychotic adult subjects with schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS).</p> <p>Secondary:</p> <ul style="list-style-type: none"> • To evaluate the efficacy of flexibly-dosed SYM-23 (50 or 75 mg/day) compared with placebo in acutely psychotic adult subjects with schizophrenia as measured by: • Clinical Global Impression-Severity (CGI-S) • PANSS subscale scores (positive, negative, and general psychopathology) • Brief Negative Symptom Scale (BNSS) • Montgomery-Asberg Depression Rating Scale (MADRS) • To evaluate the safety and tolerability of SYM-23 (50 or 75 mg/day) using • physical examinations (PE) • 12-lead electrocardiograms (ECG) • vital signs • adverse event (AE) reports • clinical laboratory results • body weight and body mass index (BMI) • Columbia – Suicide Severity Rating Scale (C-SSRS)
Methodology	<p>In a 1:1 ratio, the treatment group will be divided within each clinical center, randomized, double-blind, parallel-group study evaluating SYM-23's effectiveness and safety in acutely psychotic adult subjects with schizophrenia using SyM-24 (50 or 75 mg/day [ie, once daily] for randomized control. The study will consist of three phases: Screening/Washout (up to 14 days), Intervention (4 weeks in-patient), and a Follow-up visit (7 days after the last research drug dose for patients who stop smoking before or not enroll in the open-label extension study [SYM-202]) as shown in Figure 1.</p>

<p>Number of Patients</p>	
<p>Diagnosis and Main Criteria for Inclusion</p>	<p>Diagnosis and Main Criteria for Subject Inclusion:</p> <p>See Section 8 of full protocol for the complete list of inclusion and exclusion criteria information.</p> <p>Inclusion criteria (not all inclusive):</p> <p>To qualify for participation, subjects must meet all of the following inclusion criteria:</p> <ul style="list-style-type: none"> • Male or female subject between 18 to 40 years of age (inclusive) at the time of consent. • Subject meets DSM-5 criteria for schizophrenia as established by clinical interview (using the DSM-5 as a reference and confirmed using the SCID-CT). The duration of the subject's illness whether treated or untreated must be ≥ 6 months. • Subject must have a CGI-S score ≥ 4 (moderate or greater) at screening and Baseline (Day 1). • Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 (moderate) on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content at screening and Baseline (Day 1). • Subject has an acute exacerbation of psychotic symptoms (no longer than 2 months). • Subject has marked deterioration of functioning in one or more areas, such as occupational, social, or personal care or hygiene. • Subject requires hospitalization for an acute psychotic exacerbation at the time of screening or has been hospitalized for the purpose of treating an acute psychotic exacerbation for no more than 2 consecutive weeks immediately before screening. <p>Subjects who have been hospitalized for more than 2 weeks for reasons unrelated to acute psychotic exacerbation may be included if such a hospitalization was for a condition other than an acute psychotic relapse. For example, subjects in a long-term hospital setting who have an acute exacerbation and are transferred to an acute unit are eligible for the study.</p> <ul style="list-style-type: none"> • Subject has had no more than 2 prior hospitalizations for the treatment of an acute exacerbation of schizophrenia (not including the current hospitalization). This history must be confirmed based on report by a reliable informant (eg. caregiver or family member) or

	<p>medical records available at the time of screening.</p> <ul style="list-style-type: none"> • At Baseline, subject must have a total score < 5 on the SAS.
Test Product, Dose and Mode of Administration	<p>Name of Investigational Product:</p> <p>SYM-23</p> <p>Investigational Product, Dosage and Mode of Administration:</p> <p>SYM-23 treatment will be size 0, Swedish-orange capsules (50 mg or 75 mg) administered orally once daily. Study drug will be taken at the same time each evening before bed time and may be taken with or without food. Subjects will receive SYM-23 50 mg/day on Day 1 through 3. On Day 4, subjects are permitted (but not required) to titrate up to a dose of 75 mg/day. Thereafter, if a dose increase is necessary to optimize efficacy it should occur at regular scheduled study visits/weekly intervals starting from Visit 4 based on Investigator judgement. A dose reduction for tolerability purposes is permitted to occur more frequently than at weekly intervals. Subject can be flexibly dosed up until Visit 6, with no dose adjustments allowed thereafter.</p>
Reference Therapy, Dose, Mode of Administration, and Batch Numbers	<p>Matching placebo treatment will be size 0, Swedish-orange capsules administered orally once daily. Study drug will be taken at the same time each evening before bed time and may be taken with or without food. Subjects randomized to placebo will receive placebo throughout the study.</p>
Duration of Treatment	<p>4 weeks</p>
Criteria for Evaluation	<p>The CBB will assess the effect of SYM-23 on cognition by collecting physical examination (PE) results, ECGs, vital signs, AEs, clinical laboratory data, C-SSRS, and MADRS scores throughout the study. Subjects with significant findings for suicidal ideation after completion of the C-SSRS at any time during the study must be referred to the researcher for follow-up analysis by using the AIMS, BARS, and SAS scales. POPPK measurements for plasma SYM-23 and SyM-22 concentrations will be collected on Day 1 (predose) and Page 29; the results of which will not be announced separately. The effect of cytochrome (CYP) P450 metabolizer status on plasma SYM-23 exposure using population PK/pharmacodynamics (PD) methods exposure will be investigated and reported separately.</p>
Bio-analytical Methods	
Statistical Methods	Statistical Methods:

The change from Baseline to Test Effects (mITT) population, which includes all subjects that are random, have received at least one dose of study drug, and have performed at minimum one post-Baseline evaluation in PANSS or CGI-S, is the measurement of safety. The Safety population will be based on the change between Baselines' testing superiority of SYM-23 relative to placebo, according to the current research findings. The MMRM's primary outcome variable will be determined as a covariate, and the Kenward-Rogers approximation will determine the denominator degree of freedom for the treatment, visit (Day 4, Weeks 1, 2, 3, and 4; as an identifiable attribute), pooled center, study-by-visit interaction, etc. The secondary effect variables of change from Baseline's CGI-S score, PANSS subscale scores, BNSS total score and MADRS total rank will be determined similarly to the primary endpoint. Baseline PANSS total score, including laboratory results, clinical findings, and C-SSRS will be summarized as the dependent variable in this case. AEs will be further described by severity and in relation to the study drug, as well as any adverse events that occurred before or after the first dose of study medication. A nonparametric rank analysis of covariance (ANCOVA) will be applied to prolactin, HbA1c, lipids, and glucose levels, as well as body weight and BMI in order to compare changes from Baseline to treatment groups with adjustments for Baselines.

Sample Size:

Based on a review of published research into other antipsychotics for the short-term treatment of schizophrenia, 80% power will be found in change from Baseline in PANSS total score at Week 4 for SYM-23 and placebo) with t-test method with two independent sample randomized design methods with 2-sided significant difference size of 0.05 was expected. The total sample size will be 240 random subjects (or 120 subjects per treatment group), with an upward adjustment of the sample number being used to compensate for missing data from subjects that are randomly chosen and discontinue from the study.

RESULTS

Disposition:

Efficacy:

Safety:
CONCLUSIONS
Date of Report: 08-02-2023

3 Table of Contents

LIST OF IN-TEXT TABLES AND FIGURES

TSFAE01A Overall Summary of Treatment-emergent Adverse Events; Double-blind Induction Phase (Study 54135419TRD2005: Safety [DB] Analysis Set)

TSFAE01B Overall Summary of Adverse Events; Double-blind Follow-up Phase (Study 54135419TRD2005: FU [DB] Analysis Set)

TSFAE01C Overall Summary of Adverse Events; Post Treatment Phase (Study 54135419TRD2005: Safety [responders] Analysis Set)

TSFAE01D Overall Summary of Adverse Events; Within 4-Week After Double-blind Induction Phase (Study 54135419TRD2005: Safety [DB] Analysis Set)

TSFAE01E Overall Summary of Treatment-emergent Adverse Events; Open-label Induction Phase (Study 54135419TRD2005: Safety [OL] Analysis Set)

TSFAE02A Treatment-emergent Adverse Events by MedDRA System Organ Class and Preferred Term; Double-blind Induction Phase (Study 54135419TRD2005: Safety [DB] Analysis Set)

TSFAE02F Adverse Events by MedDRA System Organ Class and Preferred Term; Open-label Follow-up Phase (Study 54135419TRD2005: FU [OL] Analysis Set)

TSIDEM01A Number of Subjects in Each Analysis Set; Double-blind Induction/Follow-up and Post Treatment Phases (Study 54135419TRD2005: All Randomized Analysis Set)

TSIDEM03A Demographic and Baseline Characteristics (Study 54135419TRD2005: FAS [DB] Analysis Set)

TSIDS01A Study Completion/Withdrawal Information; Double-blind Induction Phase (Study 54135419TRD2005: All Randomized Analysis Set)

TSIDS02 Study Disposition (Study 54135419TRD2005: All Subjects)

4 List of Abbreviations & Definition of Terms

Abbreviations	Terms
5-HT	5-hydroxytryptamine (serotonin)
AE	Adverse event
AIMS	Abnormal Involuntary Movement Scale
ALT	Alanine aminotransferase
ANCOVA	Analysis of covariance
AST	Aspartate aminotransferase
ATC	Anatomical Therapeutic Chemical
BARS	Barnes Akathisia Rating Scale
BLQ	Below the Lower Limit of Quantification
BMI	Body mass index
BNSS	Brief Negative Symptom Scale
BOLD	Blood oxygen level dependent
BUN	Blood urea nitrogen
C-SSRS	Columbia – Suicide Severity Rating Scale
CBB	Cogstate Brief Battery

CDR	Clinical data repository
CFR	Code of Federal Regulations
CGI-I	Clinical global impression - improvement
CGI-S	Clinical global impression - severity
CI	Confidence Interval
CLIA	Clinical Laboratory Improvement Amendments
CNS	Central nervous system
CRF	Case report form
CRO	Contract research organization
CS	Clinically significant
CSP	Clinical Study Protocol
CYP	cytochrome
DEQ	Drug Effects Questionnaire
DMC	Data Monitoring Committee
DSM-5	Diagnostic and Statistical Manual of Mental Disorder, 5 th Edition
ECG	Electrocardiogram
EDC	Electronic data capture
EEG	Electroencephalogram
ET	Early termination

FDA	U.S. Food and Drug Administration
fMRI	functional magnetic resonance imaging (fMRI)
GCP	Good Clinical Practice
HIV	Human immunodeficiency virus
HLT	High Level Term
HR	Heart Rate
ICH	International Conference on Harmonization
IEC	Independent Ethics Committee
IND	Investigational New Drug
IPD	Important protocol deviation
IRB	Institutional Review Board
IXRS	Interactive voice/web response system
LIMS	Laboratory information management system
LOCF	Last Observation Carried Forward
LS	Least Squares
MADRS	Montgomery-Asberg Depression Rating Scale
MAR	Missing At Random
MCMC	Markov Chain Monte Carlo
MedDRA	Medical Dictionary for Regulatory Activities

MID	Monetary incentive delay
mITT	Modified Intention-to-Treat
MMRM	Mixed-effects Models Repeated Measures
MoA	Mechanism of action
MTD	Maximum tolerated dose
N2	NREM sleep stage 2
N3	NREM sleep stage 3
NCS	Not clinically significant
NREM	Non-rapid eye movement sleep
PANSS	Positive and negative syndrome scale
PD	Pharmacodynamic(s)
PE	Physical examination
PGx	Pharmacogenomic(s)
PK	Pharmacokinetic(s)
PMM	Pattern Mixture Model
POPPK	Population pharmacokinetics
PP	Per Protocol
PR	Time between P wave and QRS in electrocardiography
PSG	polysomnography

PSQI	Pittsburgh Sleep Quality Index
PT	Preferred term
QD	Once daily
QRS	Electrocardiographic wave (complex or interval)
QT	Electrocardiographic interval from the beginning of the QRS complex to the end of the T wave
QTc	QT interval corrected for heart rate
REM	Rapid eye movement
RR	Respiration rate
SAD	single ascending dose
SAE	Serious adverse event
SAP	Statistical Analysis Plan
SAS	Simpson-Angus Scale
SCID-CT	Structured Clinical Interview for DSM-5, Clinical Trials Version
SE	Standard Error
SI	International System of Units
SOC	System organ class
TAAR1	trace amine associated 1 receptors
ULQ	Above the Upper Limit of Quantification
UPSM	Uncorrelated PANSS Score Matrix

US, USA	United States, United States of America
USP	United States Pharmacopeia
VAS	Visual analogue scale
WBC	White blood cells
WHO	World Health Organization

5 Ethics and Regulatory Approval

5.1 Independent Ethics Committee Approval

The study protocol and all its amendments, and the patient information sheet(s) were reviewed and approved by the appropriate independent ethics committees as detailed in table one below.

Table 1: Ethics committees

Centre name and number		
Investigator		
Ethics committee		
Chairman		
Date of approval of the final protocol		
Date of approval of amendment 1		
Date of approval of amendment 2		
Date of approval of amendment 3		

Please fill the section

5.2 Ethical Conduct of the Study

The study was performed in accordance with the current version of the declaration of Helsinki (52nd WMA General Assembly, Edinburgh, Scotland, October 2000). The trial was conducted in agreement with the International Conference on Harmonization (ICH) guidelines on Good Clinical Practice (GCP)

5.3 Patient Information and Consent

All patients provided written informed consent to participate in the study prior to being screened. The patient information sheet detailed the procedures involved in the study (aims, methodology, potential risks, anticipated benefits) and the investigator explained these to each patient. The patient signed the consent form to indicate that the information had been explained and understood. The patient was given the opportunity to consider the information presented before signing and dating the informed consent form to indicate that he/she fully understood the information, and willingly volunteered to participate in the study. The patient was given a copy of the informed consent form for his/her information. The original copy of the informed consent was kept in a confidential file in the Investigators centre records. A sample of the patient information sheet and consent form can be found in Appendix *[insert]*

6 Investigators and Study Administrative Structure

Table 2 shows the principal study personnel involved in the study.

Table 2: Principal study personnel

Title	Name and affiliation
Principal Investigator	
Sponsor	
Project Managers	
Project Leaders	
Clinical Research Associate(s)	
Medical Adviser	
Laboratory investigator	
Data Management	

Table 3: Organizations Critical to the conduct of the study

Responsibility	Name	Address
eg, data cleaning		
eg, medical writing		

Please fill the section

7 Introduction

7.1 Rationale for the Study

SYM-23 is a CNS-active compound, which shows broad efficacy in animal models of schizophrenia (positive and negative symptoms), cognition and depression. The molecular target responsible for the profile effects has not been completely elucidated, but may include actions at 5-HT_{1A} and trace amine associated 1 (TAAR1) receptors. Rat electroencephalogram (EEG) studies showed that SYM-23 suppressed rapid eye movement (REM) sleep in a dose dependent manner. In nonhuman primate functional magnetic resonance imaging (fMRI) experiments, similar to risperidone, pretreatment with SYM-23 also reduced the ketamine brain fMRI response in rhesus monkey supporting an antipsychotic-like profile. Taken together, these data demonstrate that SYM-23 exhibits clear, functional CNS PD signals in rats and nonhuman primates.

To date, 210 subjects have received oral doses of SYM-23 in six Phase 1 clinical studies. Five Phase 1 studies have been completed (SYM-101, SYM-103, SYM-105,

SYM-106, and SYM-108). One Phase 1 study has been clinically completed (SYM-104). The first in human clinical study, a single ascending dose study (SAD; Study SYM-101), was designed to determine the safety, tolerability, maximum tolerated dose (MTD), and PK of a single oral dose of SYM-23 in normal, healthy, adult male subjects.

Study SYM-103 was a randomized, double-blind, placebo-controlled, crossover polysomnography (PSG) study that investigated the effect of a single oral dose (50 mg and 10 mg) of SYM-23 on REM sleep suppression and PK in healthy adult male subjects. A single 50 mg oral dose of SYM-23 suppressed REM sleep in all subjects (increased latency to REM sleep and reduced time spent in REM sleep) and increased NREM sleep stage 2 (N2), and NREM sleep stage 3 (N3) (deep or slow wave sleep). A single oral 10 mg dose of

SYM-23 also increased latency to REM sleep to a lesser extent, but did not reduce time spent in REM sleep. Taken together, results from these 2 studies in healthy adult male subjects demonstrated acceptable safety profile as well as robust CNS effect.

Study SYM-105 was a randomized, single-blind, placebo-controlled, SAD study assessing the safety, tolerability, and PK of SYM-23 in male and female subjects with schizophrenia.

Study SYM-106 was a 2-part, randomized, single-blind, placebo-controlled, multiple ascending oral dose (MAD) and open-label study in male and female schizophrenic patients assessing the safety, tolerability, and PK of SYM-23 in the target patient population. Results from this study demonstrate an acceptable safety and tolerability profile of SYM-23 up to 28 days in schizophrenia patients.

Additionally, in Part 2, treatment with SYM-23 at 75 mg/day for 28 days demonstrated improvement in efficacy measures (PANSS total score, CGI-S) compared with Baseline. Furthermore, ad hoc subgroup analyses showed a significantly greater decrease from Baseline in PANSS total scores at the end of the 28 day treatment period in subjects who had less frequent hospitalizations per year of illness compared with subjects who had more frequent hospitalizations per year of illness.

Study SYM-104 was a randomized, double-blind, placebo-controlled, single dose study of the effects of SYM-23 (50 mg) and amisulpride (400 mg) on BOLD-fMRI signal in healthy adult male and female subjects with high or low schizotypal characteristics. Subjects with high schizotypal characteristics and patients with schizophrenia share many similar features including positive, cognitive, negative and anhedonia symptoms, although in high schizotypes the features present in an attenuated form. In this study, fMRI was used in combination with a validated monetary incentive delay (MID) task to examine

the single dose effects SYM-23 on changes in reward processing. During the anticipation/motivational phase of the task, SYM-23 modulated striatum, insula and orbitofrontal cortex brain activity, and fMRI effects of

SYM-23 were similar to those observed with the D2 antagonist amisulpride. During the outcome/hedonic phase of the task, SYM-23 generally increased brain activity in core reward areas (striatum, insula), whereas amisulpride decreased brain activity in these same regions. Taken together the overall pattern of activity during MID task performance support specific hypotheses for the potential of SYM-23, a novel MoA molecule, to improve positive and negative symptoms of schizophrenia. Overall, the known molecular pharmacology profile, animal model evidence, and clinical experience in healthy adult male and female subjects, adult male and female subjects with high and low schizotypic characteristics, and patients with schizophrenia provide further support to evaluate SYM-23 as a potential treatment for schizophrenia.

The present study is designed to evaluate efficacy and safety of SYM-23 50 and 75 mg/day for 4 weeks in adult male and female subjects with an acute exacerbation of schizophrenia.

8 Study Objectives

8.1 Primary Objective

To evaluate the efficacy of flexibly dosed SYM-23 (50 or 75 mg/day) compared with placebo in acutely psychotic adult subjects with schizophrenia as measured by the Positive and Negative Syndrome Scale (PANSS).

8.2 Secondary Objective

- To evaluate the efficacy of flexibly dosed SYM-23 (50 or 75 mg/day) compared with placebo in acutely psychotic adult subjects with schizophrenia as measured by:
 - Clinical Global Impression-Severity (CGI-S)
 - PANSS subscale scores (positive, negative, and general psychopathology)
 - Brief Negative Symptom Scale (BNSS)
 - Montgomery-Asberg Depression Rating Scale (MADRS)
- To evaluate the safety and tolerability of flexibly dosed SYM-23 (50 or 75 mg/day) using:
 - physical examinations (PE)
 - 12-lead electrocardiograms (ECG)
 - vital signs
 - adverse event (AE) reports
 - clinical laboratory results
 - body weight and body mass index (BMI)
 - Columbia – Suicide Severity Rating Scale (C-SSRS)

9 Investigational Plan


9.1 Overall Study Design and Plan

This is a multicenter, randomized, double-blind, parallel-group, flexibly-dosed, study evaluating the efficacy and safety of SYM-23 in acutely psychotic adult subjects with schizophrenia using SYM-23 (50 or 75 mg/day [ie, once daily]) versus placebo over a 4-week treatment period. This study is projected to randomize at least 240 subjects to 2 treatment groups (SYM-23 or placebo) in a 1:1 ratio. Treatment assignment will be balanced within each clinical site. Subjects randomized to placebo will receive placebo treatment throughout the study. Study drug will be dosed at bed time with or without food.

The study will consist of 3 periods: Screening/Washout (up to 14 days), Treatment (4 weeks in-patient), and a Follow-up visit (7 days after last study drug dose for subjects who discontinue prior to Visit 7 or who complete the study but do not elect to enroll in the open-label extension study [SYM-202]).

A study schematic is presented in Figure 1. Details of the study assessments and other procedures to be performed at each visit are presented in Table 2, Schedule of Assessments, and Section 11, Study Assessments. If necessary, subjects may return to the clinic at any time for an unscheduled visit.

Figure 1: Study Schematic



* Screening/washout period will be up to 14 days.

** Follow-up visit 7 ± 2 days after last dose only for subjects not continuing in to open-label extension study SYM-202. Hospitalization will be allowed for up to an additional 7 days to stabilize the subject, if necessary

Screening/Washout Period (up to 14 days)

Informed consent will be obtained from each subject before any study procedures are performed. Subjects will be evaluated for eligibility during a screening phase of up to 14 days, during which they will be tapered off all psychotropic medications (except as noted in the protocol) in a manner that is

consistent with labeling recommendations and conventional medical practices. Subjects will remain hospitalized for the duration of the screening/washout period.

Double-Blind Treatment Period (4 weeks)

During the double-blind phase, subjects will be in-patient through Week 4. Subjects will be eligible for hospital discharge after the Week 4 visit (Day 29).

Randomization/Treatment: At double-blind Baseline (Day 1), subjects who have successfully completed the washout of prior medication (see Section 10.3.1) and have met the randomization criteria (see below) will be randomly assigned via interactive web/voice response system (in a 1:1 ratio) to one of two treatment arms: SYM-23 or placebo. Study drug dosing will initiate the evening of the Baseline visit. Treatment will continue once-daily at night for the remainder of study during which procedures outlined in Table 2 will be conducted.

Subjects will receive SYM-23 50 mg/day on Day 1 through 3. On Day 4, subjects are permitted (but not required) to titrate up to a dose of 75 mg/day. Thereafter, if a dose increase is necessary to optimize efficacy it should occur at regular scheduled study visits/weekly intervals starting from Visit 4 based on Investigator judgement. A dose reduction for tolerability purposes is permitted to occur more frequently than at weekly intervals. Subject can be flexibly dosed up until Visit 6, but no dose adjustments are allowed thereafter.

End of Double-Blind Period:

Subjects who complete the 4-week double-blind treatment phase will be eligible to participate in a separate open-label 26-week extension study (Study SYM-202). Subjects who discontinue early from the study or complete the study and do not enter the 6-month extension study will be required to complete the follow-up visit 7 days (± 2 days) post last dose of study drug.

Upon completion or early discontinuation from the study, hospitalization will be allowed for up to an additional 7 days to stabilize the subject, if necessary. Prior authorization for the hospitalization must be approved by the Medical Monitor. After completion of the follow-up visit or upon study discontinuation, all subjects will be referred for appropriate continued treatment and follow-up care as determined by the Investigator.

Efficacy, Safety, and Pharmacokinetic Evaluations

Efficacy will be evaluated using the PANSS total and subscale scores, as well as CGI-S, BNSS, and MADRS scores. Effect of SYM-23 on cognition will be assessed by the CBB.

Safety and tolerability will be monitored throughout the study by collection of PE results, ECGs, vital signs, AEs, clinical laboratory parameters, C-SSRS, body weight, and BMI. Subjects who have significant findings for suicidal ideation upon completion of the C-SSRS at any time during the study must be referred to the investigator for follow-up evaluation.

Subjects will provide information on subjective drug effects via administration of the DEQ. In addition, effects on movement disorders will be measured using the AIMS, BARS and SAS scales. Subjective effects on sleep will be measured by the PSQI scale.

Blood samples for plasma SYM-23 and SYM-22 concentrations will be collected on Day 1 (predose) and Day 29. POPPK analysis will be performed using plasma SYM-23 concentrations; the results of which will be reported separately. The relationship between PANSS total score and plasma SYM-23 exposure using population PK/pharmacodynamics (PD) methods exposure will be explored and reported separately. The impact of cytochrome (CYP) P450 CYP2D6 metabolizer status on plasma SYM-23 exposure will be explored and reported separately.

9.1.1 Study Timing

Please fill or remove the Subsection in the Template

9.1.2 Study Location

Please fill or remove the Subsection in the Template

9.2 Discussion of Study Design

This is a multiregional, randomized, double-blind, parallel-group, flexibly-dosed study evaluating the efficacy and safety of SYM-23 in acutely psychotic adult subjects with schizophrenia using SYM-23 (50 or 75 mg/day) versus placebo over a 4-week treatment period. The 4-week study duration will provide an adequate timeframe within which to evaluate the effects of SYM-23 compared to placebo in this subject population.

9.3 Selection of Study Population

9.3.1 Inclusion Criteria

To qualify for participation, subjects must meet all of the following inclusion criteria:

1. Subject must give written informed consent and privacy authorization prior to participation in the study. Separate consent will be obtained from a caregiver or legal guardian if required by local law.
2. Subject must be willing and able to comply with the study procedures and visit schedules, including required hospitalization for the washout period and the double-blind treatment period, and must be able to understand and follow verbal and written instructions.
3. Male or female subject between 18 to 40 years of age (inclusive) at the time of consent.
4. Subject meets DSM-5 criteria for schizophrenia as established by clinical interview (using the DSM-5 as a reference and confirmed using the SCID-CT). The duration of the subject's illness whether treated or untreated must be ≥ 6 months.
5. Subject must have a CGI-S score ≥ 4 (moderate or greater) at screening and Baseline (Day 1).
6. Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 (moderate) on 2 or more of the following PANSS items: delusions, conceptual disorganization, hallucinations, and unusual thought content at screening and Baseline (Day 1).

7. Subject has an acute exacerbation of psychotic symptoms (no longer than 2 months).

- Subject has marked deterioration of functioning in one or more areas, such as occupational, social, or personal care or hygiene.
- Subject requires hospitalization for an acute psychotic exacerbation at the time of screening or has been hospitalized for the purpose of treating an acute psychotic exacerbation for no more than 2 consecutive weeks immediately before screening.

Subjects who have been hospitalized for more than 2 weeks for reasons unrelated to an acute psychotic exacerbation may be included if such a hospitalization was for a condition other than an acute psychotic relapse. For example, subjects in a long-term hospital setting who have an acute exacerbation and are transferred to an acute unit are eligible for the study.

8. Subject has had no more than 2 prior hospitalizations for the treatment of an acute exacerbation of schizophrenia (not including the current hospitalization) This history must be confirmed based on report by a reliable informant (eg., caregiver or family member) or medical records available at the time of screening.

9. Subject's BMI must be at least 18 kg/m² but no more than 35 kg/m².

10. Female subject must have a negative serum pregnancy test at screening.

11. Female subject of reproductive potential agrees to remain abstinent or use highly effective and reliable contraception throughout the study and for at least 30 days after the last dose of study drug has been taken (See Section 21 Appendix II Highly Effective

Contraceptive procedures). In the Investigator's judgment, the subject will adhere to this requirement.

12. Male subjects with female partner(s) of childbearing potential must agree to avoid fathering a child and use highly effective methods of birth control (outlined in

Section 21) from screening until at least 30 days after the last study drug administration.

13. Subject must be able and agree to remain off prior antipsychotic medication for the duration of the study.

14. Subject must have a total score < 5 on the SAS at Baseline (Day 1).

15. Subject is, in the opinion of the Investigator, generally healthy based on screening medical history, PE, neurological examination, vital signs, clinical laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin).

16. Subject has had a stable living arrangement at the time of screening and agrees to return to a similar living arrangement after discharge. This criterion is not meant to exclude subjects who have temporarily left a stable living arrangement (eg, due to psychosis). Such subjects remain eligible to participate in this protocol. Chronically homeless subjects should not be enrolled.

17. Subject must agree to comply with all restrictions for the required length of time (see Concomitant Medications and Restrictions in Section 10.3).

9.3.2 Exclusion Criteria

To qualify for participation, subjects must not meet any of the following exclusion criteria:

1. Subject answers “yes” to “Suicidal Ideation” Item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at or during the Screening period (ie, in the past one month) and/or at Baseline (ie, since last visit).
2. Subject does not tolerate venipuncture or has poor venous access that would cause difficulty for collecting blood samples.
3. Subject is currently participating, or has participated in, a study with an investigational or marketed compound or device within 6 months prior to signing the informed consent, or has participated in 2 or more studies within 24 months prior to signing informed consent.
4. Subject has previously received SYM-23.
5. Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject’s ability to complete and/or participate in the study:
 - a. Hematological (including deep vein thrombosis) or bleeding disorder, renal, metabolic, endocrine, pulmonary, gastrointestinal, urological, cardiovascular, hepatic, neurologic, or allergic disease that is clinically significant or unstable (except for untreated, asymptomatic, seasonal allergies at time of dosing).
 - b. Subject has a history of neuroleptic malignant syndrome.
 - c. Subject has a history of malignancy within 5 years prior to the Screening visit, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Pituitary tumors of any duration are excluded.
 - d. Disorder or history of a condition, or previous gastrointestinal surgery (eg, cholecystectomy, vagotomy, bowel resection, or any surgical procedure) that may interfere with drug absorption, distribution, metabolism, excretion, gastrointestinal motility, or pH, or a clinically significant abnormality of the hepatic or renal system, or a history of malabsorption.
 - e. Subject has Alcohol or Substance Abuse Disorder (DSM-5 criteria). The only exceptions include caffeine or nicotine.
 - f. Subject has a clinically significant abnormal 12-lead ECG that may jeopardize the subject’s ability to complete the study or a screening 12-lead ECG demonstrating any one of the following: heart rate > 100 beats per minute, QRS > 120 ms, QT interval corrected for heart rate using Fridericia’s formula (QTcF) > 450 ms (males), QTcF > 470 ms (females), or PR > 220 ms.

g. Subjects with known history of human immunodeficiency virus (HIV) seropositivity.

6. Female subject who is pregnant or lactating.
7. Subject who has a lifelong history or presence of symptoms consistent with a major psychiatric disorder other than schizophrenia as defined by DSM-5. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, major depressive disorder, bipolar depression, mania, schizoaffective disorder, obsessive compulsive disorder, posttraumatic stress disorder. Previous or current symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms have not been a focus of primary treatment.
8. Subject tests positive for drugs of abuse at screening, however, a positive test for amphetamines, barbiturates, opiates, benzodiazepines may not result in exclusion of subjects if the investigator determines that the positive test is as a result of prescription medicine(s). In the event a subject tests positive for cannabinoids (tetrahydrocannabinol), the Investigator will evaluate the subject's ability to abstain from using this substance during the study. This information will be discussed with the Medical Monitor prior to study enrollment.
9. Subject is at significant risk of harming self, others or objects based on the Investigator's judgment.
10. Subject has attempted suicide within 3 months prior to screening.
11. Subject is involuntarily hospitalized.
12. Subject has received depot antipsychotics unless the last injection was at least one treatment cycle or at least 30 days (whichever is longer), prior to the screening phase.
13. Subject is judged to be resistant to antipsychotic treatment by the Investigator, based on failure to respond to 2 or more marketed antipsychotic agents, given at adequate dose for at least 4 weeks within a 1 year period prior to Screening.
14. Subject has a history of treatment with clozapine for refractory psychosis and/or subject has been treated with clozapine (for any reason) within 4 months of Screening.
15. Subject is receiving a total dose of antipsychotic medication equivalent to ≥ 12.0 mg/day of haloperidol at Screening (see Section 22, Appendix III for table of haloperidol dose equivalents). Subject may be eligible if such treatment is less than 2 weeks in duration after consultation with the Medical Monitor.
16. Subject has received electroconvulsive therapy treatment within the 3 months prior to screening or is expected to require ECT during the study.
17. Subject takes or has taken other disallowed recent or concomitant medications (see Section 10.3). Subjects must taper off antipsychotic medications by Day -1.
18. Subject has a history of allergic reaction or suspected sensitivity to any substance that is contained in the formulation (gelatin).

19. Subject has any clinically significant abnormal laboratory values (hematology, serum chemistry, urinalysis, lipid panel, coagulation panel, thyroid panel, and serum prolactin (Note: abnormal findings that may be clinically significant or of questionable significance will be discussed with the Medical Monitor prior to including subject)).

20. Subject demonstrates evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation.

Note: Subjects with serum alanine transaminase (ALT) or aspartate transaminase (AST) levels ≥ 3 times the upper limit of the reference ranges provided by the central laboratory require retesting. If on retesting, the laboratory value remains ≥ 3 times the upper limit, the subject will be excluded.

21. Subject has a serum blood urea nitrogen (BUN) or serum creatinine (Cr) value ≥ 1.5 times the upper limit of normal for the reference range.

22. Subject has experienced significant blood loss (≥ 473 mL) or donated blood within 60 days prior to first dose of study drug; has donated plasma within 72 hours prior to the first dose of study drug or intends to donate plasma or blood or undergo elective surgery during study participation or within 60 days after the last study visit.

23. Subject has used disallowed prescription or disallowed nonprescription drugs, vitamins, or dietary or herbal supplements within 14 days prior to dosing or anticipates the need for any disallowed medication during their participation in this study [exception: female subjects who are taking oral, patch, or intrauterine device (IUD) hormonal contraceptives, or progestin implant or injection].

24. Subject is a staff member or the relative of a staff member.

25. Subjects with a fasting blood glucose at screening ≥ 126 mg/dL (7.0 mmol/L) or HbA_{1c} $\geq 6.5\%$ will be excluded.

26. Subject has a prolactin concentration > 100 ng/mL at screening or has a history of pituitary adenoma. **NOTE:** Subjects with prolactin levels > 100 ng/mL and ≤ 200 ng/mL at the Screening visit are permitted to enroll after discussion with the Medical Monitor to ensure exclusion of non-psychotropic drug-related causes of elevated prolactin levels.

27. Subject is in the opinion of the Investigator, unsuitable in any other way to participate in this study.

9.3.3 Removal of Patients from Therapy or Assessment

Criteria for Study Drug Discontinuation

Subjects may be discontinued from the study drug at any time for any of the following reasons:

- Adverse event (specify)
- Lack of efficacy (specify)
- Withdrawal by subject (specify)

- Non-compliance with study drug (specify)
- Protocol deviation (specify)
- Death
- Progressive disease
- Pregnancy
- Other (specify)

If at any time during the course of the study, in the opinion of the Investigator, the subject may no longer safely participate due to a change in medical status (eg, experiences an AE, becomes pregnant), the subject must be discontinued from the study drug.

The reason and information on the epoch for study drug discontinuation will be recorded on the appropriate CRF. In case of death, the date of death should be captured on the CRF.

Clinical Assessments After Study Drug Discontinuation

Subjects who have not received study drug will not be followed up on leaving the study.

For subjects who have received study drug and who prematurely discontinue from the study treatment (ie, do not complete through Visit 7), every effort should be made to complete the final evaluation procedures, in accordance with the early termination (ET) visit described in Section 11.8.5.

Subjects who complete the study but do not elect to enroll in the open-label extension study (Study SYM-202) and those subjects who discontinue the study early will complete a follow up visit 7 (± 2) days after the last visit to assess any post study discontinuation adverse effects as described in Section 11.8.6.

9.4 Treatments

9.4.1 Treatments Administered

Please fill or remove the Subsection in the Template

9.4.2 Description of Investigational Product{s}

Table 5: Investigational Product

Attribute	Investigational Product		
Product name	SYM-23	SYM-23	Placebo
Dosage form	Capsule	Capsule	Capsule
Unit dose	50 mg	75 mg	NA
Route of administration	Oral	Oral	Oral

Physical description	Size #0, Swedish Orange Capsule	Size #0, Swedish Orange Capsule	Size #0, Swedish Orange Capsule
Excipients	None	None	Microcrystalline cellulose

9.4.3 Method of Assigning Patients to Treatment Groups

Treatment Assignment

The randomization schedule will be generated by a non-study biostatistician. Once a subject is deemed eligible to be randomized at Day 1 (Visit 2), an IXRS will perform treatment assignment. Subjects will be randomized to one of the following treatment groups in a 1:1 ratio and balanced within each clinical site:

- SYM-23 (50 or 75 mg/day flexible dosing for 4 weeks)
- Placebo (once daily for 4 weeks)

Once a randomization number has been assigned, it cannot be reused.

Blinding

Subjects, Investigator staff, persons performing the assessments, clinical operations personnel, data analysts, and personnel at central laboratories (including imaging) will remain blind to the identity of the treatment from the time of randomization until database lock and unblinding, using the following methods; (1) randomization data are kept strictly confidential until the time of unblinding, and will not be accessible by anyone else involved in the study with the exception of bioanalytical personnel involved in the analysis of PK samples; (2) the identity of the treatments will be concealed by the use of study drugs that are all identical in packaging, labeling, schedule of administration and appearance.

Actual subject identity for plasma concentrations of SYM-23 and SYM-22 will not be disclosed before the database lock and the unblinding of the double-blind treatment phase.

Emergency Unblinding Procedures

In the case of a medical emergency, where knowledge of study drug by the Investigator or an authorized delegate is essential for immediate medical management, a 24-hour code-break service will be available via the IXRS. The date and reason for unblinding are to be documented in the source documents. Any subject for whom the treatment assignment was unblinded is to be discontinued from further study participation. The subject should return for a final study assessment as described in Section 11.8.6.

9.4.4 Selection of Doses in the Study

Please fill or remove the Subsection in the Template

9.4.5 Selection and Timing of Dose for Individual Patients

Please fill or remove the Subsection in the Template

9.4.6 Prior and Concomitant Therapy

See Section 10.3 for a complete description of medications permitted during the study. Site study staff will record all medications used to treat schizophrenia taken within 1 month prior to screening visit in the eCRF. Also, the following parameters will be recorded for all concomitant medications: drug name, route of administration, total daily dose, unit, frequency, start/stop dates, indication, and whether the medication was started after last dose of study medication. The prior and concomitant medications will subsequently be coded using the World Health Organization Drug Dictionary (WHO-DD).

9.4.7 Treatment Compliance

The Investigator will record the dose of the study drug and the dates of the initial and final administration for each dose.

Compliance must be monitored closely and determined at each visit. Compliance will be assessed by counting capsules and dividing the actual number of doses taken (per capsule count) by the number of doses the subject should have taken within a visit period and multiplying by 100. All subjects will be reminded of the importance of strict compliance with taking study drug for the effectiveness of treatment and for the successful outcome of the study. Subjects who miss more than 25% of scheduled doses or take more than 125% of the scheduled doses will be considered noncompliant. Evidence of noncompliance must be immediately reported to the Clinical Research Associate (CRA) and/or Medical Monitor.

9.5 Efficacy and Safety Variables

9.5.1 Efficacy and Safety Measurements Assessed

See Table 2 Schedule of Assessments, for a summary of procedures at each study visit. See Section 11.1 to Section 11.5 for detailed information on conducting assessments.

Screening: Visit 1 (Day -14 to -1); Inpatient

A unique screening number will be assigned to each subject.

The subject's eligibility assessment will be reviewed by the contract research organization's (CRO) oversight quality team along with the sponsor based on protocol specified inclusion and exclusion criteria. The sponsor will participate in the eligibility review process with the CRO to ascertain the subject's eligibility and will be copied on all communications between the CRO and the site. In the event the CRO/sponsor and site do not agree on a subject's eligibility then the subject will not be enrolled.

Subjects will be evaluated at the screening visit (1 to 14 days before the first dose of study drug) to determine their eligibility for the study. The following procedures will be conducted during this visit:

- Obtain signed informed consent and privacy authorization from the subject before conducting any other visit procedures.
- Inclusion and exclusion criteria

- Obtain demographic information
- Prior/concomitant medications
- Pretreatment events
- Medical history
- Psychiatric history/mental status
- SCID-CT
- Physical and neurological examination including height and weight; clinical site staff to calculate and record BMI
- Vital sign measurements (prior to ECG)
- Perform ECG
- Fasted blood samples for clinical laboratory evaluation (hematology, serum chemistry, serum prolactin, glycosylated hemoglobin [HbA_{1c}], glucose panel, and lipid panel).
- Blood samples for serum pregnancy test (serum human chorionic gonadotropin [β -hcG]) for female subjects and serum follicle stimulating hormone (FSH) for female subjects if menopause is suspected.
- Urine sample for urinalysis and urine drug screen (UDS)
- Duplicate subject check
- PANSS
- BNSS
- C-SSRS
- CGI-S
- AIMS
- BARS
- SAS

Procedures should be completed in the following sequence.

<u>Screening Visit</u>	<u>Visits 2 through Visit 8</u>
1. SCID-CT (study center rater)	1. PANSS (study center rater)
2. PANSS (study center rater)	2. BNSS (study center rater)
3. BNSS (study center rater)	3. MADRS (study center rater)
4. C-SSRS (study center rater)	4. C-SSRS (study center rater)

5. CGI-S (study center rater)	5. CGI-S
	6. AIMS/BARS/SAS
	7. PSQI
	8. DEQ
	9. CBB

Note: With the exception of SCID-CT and DEQ, all rating assessments will be performed by the rater using a tablet. In the event that a tablet is not available, the rating assessments will be performed by the rater using a paper version of the assessment.

Subjects found to be ineligible during Visit 1 will not be required to complete all the Visit 1 assessments and will not be followed up on leaving the study.

Subjects who screen fail may be re-screened up to two times, if judged appropriate by the Investigator.

Re-screened subjects will be re-consented and all Visit 1 procedures will be repeated.

Baseline: Visit 2 (Day 1); Inpatient

The following procedures will be conducted during this visit:

- Review inclusion and exclusion criteria and randomization criteria.
- Prior/concomitant medications.
- Randomize to treatment
- Blood sample for determination of plasma SYM-23 and SYM-22 (pre-dose)
- Vital sign measurements (prior to ECG)
- Weight and waist circumference
- Perform standard 12-lead ECG.
- Fasted blood samples for clinical laboratory evaluation (hematology, serum chemistry, serum prolactin, glucose panel and lipid panel).
- If subject signed separate genetic informed consent, collect blood samples for pharmacogenomics (CYPP450 2D6)
- Urine sample for urinalysis, UDS, and β -hcG (for female subjects).
- PANSS
- BNSS
- MADRS
- C-SSRS
- CGI-S

- AIMS
- BARS
- SAS
- PSQI
- DEQ
- CBB
- Administer study drug
- Adverse events

Visit 3 (Day 4); Inpatient

The following procedures will be conducted during this visit:

- Concomitant medications.
- Perform study drug accountability
- Vital sign measurements
- PANSS
- BNSS
- MADRS
- C-SSRS
- CGI-S
- AIMS
- BARS
- SAS
- Administer study drug
- Adverse events

Visit 4 (Week 1; Day 8), Visit 5 (Week 2; Day 15), and Visit 6 (Week 3; Day 22); Inpatient

The following procedures will be conducted during each visit (unless otherwise specified):

- Concomitant medications.
- Perform study drug accountability

- Vital sign measurements
- PANSS
- BNSS
- MADRS
- C-SSRS
- CGI-S
- AIMS
- BARS
- SAS
- Administer study drug
- Adverse events

Visit 7 (Week 4; Day 29/Early Termination); Inpatient

The following procedures will be conducted during this visit:

- Concomitant medications
- Study drug accountability
- Physical and neurological examination including
- Weight and waist circumference
- Vital sign measurements (prior to ECG).
- Perform standard 12-lead ECG.
- Fasted blood samples for clinical laboratory evaluation (hematology, serum chemistry, serum prolactin, glycosylated hemoglobin [HbA_{1c}], glucose panel, and lipid panel).
- Blood sample for determination of plasma SYM-23 and SYM-22 concentration (post dose)
- Urine sample for urinalysis, UDS, and β -hcG (for female subjects).
- PANSS
- BNSS
- MADRS

- C-SSRS
- CGI-S
- AIMS
- BARS
- SAS
- PSQI
- DEQ
- CBB
- Adverse events
- Duplicate subject check

At this visit, subjects who have completed treatment will have the option to enroll and continue treatment for an additional 26 weeks in an open-label extension study (Study SYM-202). For subjects entering the extension study, Week 4 in this study will be Baseline for the extension study and subjects will not need to return for further visits in this study.

Subjects who do not enter the extension study will complete the inpatient follow-up period.

Visit 8 (+ 7 days); Inpatient Follow-up

All subjects who discontinue early or do not elect to enroll in the open-label extension study (Study SYM-202) will have an inpatient/outpatient safety follow-up prior to discharge (7 ± 2 days) after their last dose of study drug. The following procedures will be conducted during this visit:

- Concomitant medications
- C-SSRS
- Adverse events
- Duplicate subject check

Please fill the section

9.5.2 Appropriateness of Measurements

Please fill or remove the Subsection in the Template

9.6 Data Quality Assurance

Data Collection/Electronic Data Capture (EDC)

The results from Screening and data collected during the study (except clinical laboratory test results) will be recorded in the subject's electronic CRF. Data will be entered into source documents prior to being transcribed into the CRF. This transcribing will be done once a subject has passed screening (Visit 1). Data for screen failures will not be collected. The study centers will use an EDC system that is compliant with relevant FDA regulatory requirements per 21 Code of Federal Regulations (CFR) Part 11. Password protected access to the EDC system will be via a secure website. Data queries and data corrections will be handled through the same system. All transactions within the EDC system are fully documented within an electronic audit trail. Each set of completed CRFs must be reviewed and electronically signed and dated by the Investigator or delegate.

Computerized Systems Used for Source Data

A list of the computerized systems that will be used to create, modify, maintain, archive, retrieve, or transmit source data are presented below, pursuant to the Guidance for Industry Computerized Systems Used in Clinical Investigations, May 2007.

Table 8: Computerized Systems Used for Source Data

Protocol Step	Computerized System Type or Description
Obtain informed consent	A
Review inclusion/exclusion criteria	A
Demographics	A
Prior/concomitant medication review	A
Randomize (IXRS) to treatment	E
Dispense study drug	A, E
Study drug accountability	A
Medical history	A
Psychiatric history/mental status	A
SCID-CT	A
Physical examination	A
Height	A
Vital sign measurements	A
Weight	A
Waist circumference	A
Electrocardiogram (ECG)	C
Hematology, chemistry, and urinalysis	B

Table 8: Computerized Systems Used for Source Data (Continued)

Protocol Step	Computerized System Type or Description
Serum prolactin	B

Glycosylated hemoglobin (HbA1c)	B
Glucose and Lipid panel	B
Serum follicle stimulating hormone (FSH)	B
Serum human chorionic gonadotropin (β -hCG)	B
Blood sample for pharmacogenomics (CYP450 2D6)	D
Blood sample for SYM-23 PK	D
Urine drug screen	B
Urine β -hCG (local)	A
Urine drug screen (central)	B
Positive and Negative Syndrome Scale (PANSS) – Total Score	F
Clinical Global Impression – Severity (CGI-S)	F
Montgomery-Asberg Depression Rating Scale (MADRS)	F
Columbia Suicide Severity Rating Scale (C-SSRS)	F
Drug Effects Questionnaire (DEQ)	A
Abnormal Involuntary Movement Scale (AIMS)	F
Barnes Akathisia Rating Scale (BARS)	F
Simpson-Angus Scale (SAS)	F
Brief Negative Symptoms Scale (BNSS)	F
Pittsburg Sleep Quality Index (PSQI)	F
CogState Brief Battery (CBB)	G
Pretreatment event monitoring	A
Adverse events (AE) monitoring	A
Provide meals	A
Statistical analysis	SAS®, version 9.2 or higher

A = EDC (MediData RAVE); B = LIMS; C = Core Lab Over-read; D = LIMS/ASCII; E = IXRS; F = Bracket; G = CogState.

Abbreviations: EDC = electronic data capture; CDR = clinical data repository; CIMS = Clinical Inventory Management System; IXRS = interactive response technology; IVRS = interactive voice recognition system; LIMS = laboratory information management system.

Study Monitoring

This study will be monitored from initiation to completion by the Sponsor or its representative. Monitoring will include personal visits and telephone communication to assure that the investigation is conducted according to protocol and in order to comply with ICH GCP. On-site review of CRFs will include a review of forms for completeness and clarity, and consistency with source documents available for each subject.

Audits

The study may be subject to audit by the Sponsor/designee. If such an audit occurs, the Investigator must agree to allow access to required subject records. This is dependent on the subject granting consent by signing the ICF. By signing this protocol, the Investigator grants permission to personnel from the Sponsor or its representatives for on-site monitoring and auditing of all appropriate study documentation, as well as on-site review of the procedures employed in CRF generation, where clinically appropriate.

In accordance with ICH GCP the Sponsor may select this study for audit. During the audit the Sponsor representative will carry out an inspection of centre facilities (eg, pharmacy, drug storage areas, laboratory) and review study related records in order to evaluate the study compliance with the Sponsor/centre SOPs, protocol, ICH GCP and local regulations. The Investigator or appropriate

designee must also agree to inspection of all study documents by the regulatory authorities and the IEC. Should the Investigator or appropriate designee be notified of a regulatory inspection involving this study they should notify the Sponsor immediately.

Study Documentation

Study records are comprised of source documents, CRFs, and all other administrative documents, eg, IRB/IEC correspondence, clinical study materials and supplies shipment manifests, monitoring logs, Sponsor and CRO correspondence, etc. A study specific binder will be provided with instructions for the maintenance of study records.

Source document is defined as any hand written or computer generated document that contains medical information or test results that have been collected for or are in support of the protocol specifications, eg, clinical laboratory reports, clinic notes, drug disbursement log, subject sign in sheets, subject completed questionnaires if applicable, telephone logs, ECGs, etc. All draft, preliminary and pre-final iterations of a final report are also considered to be source documents, eg, faxed laboratory reports and hard copy laboratory reports, faxed initial results and hard copy, final report.

Clinical Laboratory Certification and Normal Values

A central laboratory will be used for analysis for most of the clinical laboratory tests for this study. The central laboratory will provide the Investigator, Sponsor/CRO with laboratory certification(s), a dated copy of normal range values for the central clinical laboratory selected to analyze clinical specimens. If an exception is granted to use a local laboratory, the Investigator must supply the Sponsor/CRO with laboratory certification, lab director's curricula vitae and a current, dated copy of normal range values.

A local laboratory may optionally be used for analysis of serum pregnancy at Visit 2 in this study. The local laboratory/site personnel will provide Sponsor/P1 with laboratory certification(s) and a current dated copy of normal range values for the local clinical laboratory selected to analyse clinical specimens.

9.7 Statistical Methods Planned in the Protocol and Determination of Sample Size

9.7.1 Statistical and Analytical Plans

All statistical inference, unless otherwise stated, will be performed with two-sided tests at the significance level of 0.05, and two-sided 95% confidence intervals (CIs) will be calculated whenever appropriate.

9.7.2 Determination of Sample Size

A sample size of 100 subjects per treatment group (SYM-23 and placebo) will provide 80% power to detect a treatment effect size of 0.4 in change from baseline in PANSS total score at Week 4 for SYM-23 versus placebo, using a two independent sample t-test method with 2-sided significance level of 0.05. A clinically meaningful effect size of 0.4 was estimated based on review of published studies of other antipsychotics for the short-term treatment of schizophrenia. It is anticipated that 17% of all randomized subjects will discontinue early from the study. An upward adjustment of the sample size is thus used to compensate for missing data from subjects who are randomized and discontinue from the study. The total sample size will be 240 randomized subjects (or 120 subjects per treatment group).

9.8 Changes in the Conduct of the Study or Planned Analyses

9.8.1 Protocol Amendments

All revisions and/or amendments to this protocol must be approved in writing by the Sponsor and the appropriate IRB/IEC. The Investigator will not make any changes to the conduct of the study or the protocol without first obtaining written approval from the Sponsor and the IRB/IEC, except where necessary to eliminate an apparent immediate hazard to a study subject.

Emergency deviations or modifications may be initiated without Sponsor or IRB/IEC approval or favorable opinion, only in cases where the deviation or modification is necessary to eliminate or avoid an immediate apparent hazard to subjects. Emergency deviations or modifications must be reported to the Sponsor/CRO and the IRB/IEC immediately/within five business days of the occurrence, or in accordance with applicable regulatory requirements.

9.8.2 Changes to the Planned Analyses

The following analyses will be performed for this study:

- Final analysis

Data Monitoring Committee (DMC)

There will be no planned DMC for this study.

Interim Analysis

No interim analysis is planned for this study.

Final Analysis

The final, planned analysis identified in this SAP will be performed by QuintilesIMS Biostatistics following XXX authorization of this SAP, XXX authorization of analysis populations, database lock, and unblinding of treatment.

10 Study Population

10.1

10.2	10.3	10.4	10.5	10.6	10.7
------	------	------	------	------	------

10.8	10.9	10.10	10.11	10.12	10.13
------	------	-------	-------	-------	-------

10.14	10.15	10.16	10.17	10.18	10.19
-------	-------	-------	-------	-------	-------

10.20	10.21	10.22	10.23	10.24	10.25
-------	-------	-------	-------	-------	-------

10.26	10.27	10.28	10.29	10.30	10.31
-------	-------	-------	-------	-------	-------

10.32	10.33	10.34	10.35	10.36	10.37
-------	-------	-------	-------	-------	-------

10.38	10.39	10.40	10.41	10.42	10.43
-------	-------	-------	-------	-------	-------

10.44	10.45	10.46	10.47	10.48	10.49
-------	-------	-------	-------	-------	-------

10.50	10.51	10.52	10.53	10.54	10.55
-------	-------	-------	-------	-------	-------

10.56	10.57	10.58	10.59	10.60	10.61
-------	-------	-------	-------	-------	-------

10.62

10.1					
10.2	10.3	10.4	10.5	10.6	10.7
10.63					
10.64			10.65		
10.66			10.67		
10.68			10.69		
10.70			10.71		
10.72			10.73		
10.74			10.75		
10.76			10.77		
10.78					

10.79 Disposition of Patients

TSIDS01A: Study Completion/Withdrawal Information; Double-blind Induction Phase (Study 54135419TRD2005: All Randomized Analysis Set)

Esk 28
(N=41)
Esk 56
(N=40)
Esk 84
(N=41)
Placebo
(N=80)
Total
(N=202)
Completed
39 (95.1%)
33 (82.5%)
39 (95.1%)
72 (90.0%)

183 (90.6%)

Withdrawn

2 (4.9%)

7 (17.5%)

2 (4.9%)

8 (10.0%)

19 (9.4%)

Adverse event

1 (2.4%)

4 (10.0%)

2 (4.9%)

3 (3.8%)

10 (5.0%)

Lack of efficacy

0

0

0

2 (2.5%)

2 (1.0%)

Lost to follow-up

0

0

0

1 (1.3%)

1 (0.5%)

Non-compliance with switched

oral antidepressant therapy

0

0

0

1 (1.3%)

1 (0.5%)

Withdrawal by subject

1 (2.4%)

1 (2.5%)

0

0

2 (1.0%)

Other

0

2 (5.0%)

0

1 (1.3%)

3 (1.5%)

[TSIDS01A.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSIDS01A.SAS] 10FEB2020, 04:40

TSIDS02: Study Disposition (Study 54135419TRD2005: All Subjects)

Total

(N=460)

Screened subjects

460 (100.0%)

Subjects in prospective lead-in phase
308 (67.0%)
Randomized subjects
202 (43.9%)
Completed DB induction phase
183 (39.8%)
Responders at the end of DB induction phase
68 (14.8%)
Subjects who relapse after DB induction phase
53 (11.5%)

[TSIDS02.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSIDS02.SAS] 10FEB2020, 04:41

10.80 Protocol Deviations

Please fill or remove the Subsection in the Template

11 Efficacy Evaluation

11.1

11.2	11.3	11.4	11.5	11.6	11.7
11.8	11.9	11.10	11.11	11.12	11.13
11.14	11.15	11.16	11.17	11.18	11.19
11.20	11.21	11.22	11.23	11.24	11.25
11.26	11.27	11.28	11.29	11.30	11.31
11.32	11.33	11.34	11.35	11.36	11.37
11.38	11.39	11.40	11.41	11.42	11.43

11.44

11.45 Data Sets Analyzed

TSIDEM01A: Number of Subjects in Each Analysis Set; Double-blind Induction/Follow-up and Post Treatment Phases (Study 54135419TRD2005: All Randomized Analysis Set)

Esk 28
(N=41)
Esk 56
(N=40)
Esk 84
(N=41)
Placebo
(N=80)
Total
(N=202)
All randomized
41 (100.0%)
40 (100.0%)
41 (100.0%)
80 (100.0%)
202 (100.0%)

FAS (DB)
 41 (100.0%)
 40 (100.0%)
 41 (100.0%)
 80 (100.0%)
 202 (100.0%)
 FAS (responders)
 13 (31.7%)
 11 (27.5%)
 17 (41.5%)
 27 (33.8%)
 68 (33.7%)
 Safety (DB) (a)
 41 (100.0%)
 40 (100.0%)
 41 (100.0%)
 80 (100.0%)
 202 (100.0%)
 Safety (responders) (a)
 13 (31.7%)
 11 (27.5%)
 17 (41.5%)
 27 (33.8%)
 68 (33.7%)
 Follow-up (DB)
 27 (65.9%)
 28 (70.0%)
 24 (58.5%)
 53 (66.3%)
 132 (65.3%)

(a) One subject in the safety analysis set who was randomized to the 84 mg group received 56 mg on Day 1, 4 and 28 mg on Day 8 then withdrew due to AE on Day 11. This subject is summarized under Esk 84 treatment group in this table.
 [TSIDEM01A.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSIDEM01A.SAS] 10FEB2020, 04:38

11.46

11.47	11.48	11.49	11.50	11.51	11.52
11.53	11.54	11.55	11.56	11.57	11.58
11.59	11.60	11.61	11.62	11.63	11.64
11.65	11.66	11.67	11.68	11.69	11.70
11.71	11.72	11.73	11.74	11.75	11.76
11.77	11.78	11.79	11.80	11.81	11.82

11.46

11.47 11.48 11.49 11.50 11.51 11.52

11.83 11.84 11.85 11.86 11.87 11.88

11.89 11.90 11.91 11.92 11.93 11.94

11.95 11.96 11.97 11.98 11.99 11.100

11.101 11.102 11.103 11.104 11.105 11.106

11.107 11.108 11.109 11.110 11.111 11.112

11.113 11.114 11.115 11.116 11.117 11.118

11.119 11.120 11.121 11.122 11.123 11.124

11.125 11.126 11.127 11.128 11.129 11.130

11.131 11.132 11.133 11.134 11.135 11.136

11.137 11.138 11.139 11.140 11.141 11.142

11.143 11.144 11.145 11.146 11.147 11.148

11.149 11.150 11.151 11.152 11.153 11.154

11.155 11.156 11.157 11.158 11.159 11.160

11.161 11.162 11.163 11.164 11.165 11.166

11.167 11.168 11.169 11.170 11.171 11.172

11.46

11.47 11.48 11.49 11.50 11.51 11.52

11.173 11.174 11.175 11.176 11.177 11.178

11.179 11.180 11.181 11.182 11.183 11.184

11.185 11.186 11.187 11.188 11.189 11.190

11.191 11.192 11.193 11.194 11.195 11.196

11.197 11.198 11.199 11.200 11.201 11.202

11.203 11.204 11.205 11.206 11.207 11.208

11.209 11.210 11.211 11.212 11.213 11.214

11.215 11.216 11.217 11.218 11.219 11.220

11.221 11.222 11.223 11.224 11.225 11.226

11.227 11.228 11.229 11.230 11.231 11.232

11.233 11.234 11.235 11.236 11.237 11.238

11.239 11.240 11.241 11.242 11.243 11.244

11.245 11.246 11.247 11.248 11.249 11.250

11.251 11.252 11.253 11.254 11.255 11.256

11.257 11.258 11.259 11.260 11.261 11.262

11.46

11.47 11.48 11.49 11.50 11.51 11.52

11.263 11.264 11.265 11.266 11.267 11.268

11.269 11.270 11.271 11.272 11.273 11.274

11.275 11.276 11.277 11.278 11.279 11.280

11.281 11.282 11.283 11.284 11.285 11.286

11.287 11.288 11.289 11.290 11.291 11.292

11.293 11.294 11.295 11.296 11.297 11.298

11.299 11.300 11.301 11.302 11.303 11.304

11.305 11.306 11.307 11.308 11.309 11.310

11.311 11.312 11.313 11.314 11.315 11.316

11.317 11.318 11.319 11.320 11.321 11.322

11.323 11.324 11.325 11.326 11.327 11.328

11.329 11.330 11.331 11.332 11.333 11.334

11.335 11.336 11.337 11.338 11.339 11.340

11.341 11.342 11.343 11.344 11.345 11.346

11.347 11.348 11.349 11.350 11.351 11.352

11.46

11.47 11.48 11.49 11.50 11.51 11.52

11.353 11.354 11.355 11.356 11.357 11.358

11.359 11.360 11.361 11.362 11.363 11.364

11.365 11.366 11.367 11.368 11.369 11.370

11.371 11.372 11.373 11.374 11.375 11.376

11.377 11.378 11.379 11.380 11.381 11.382

11.383 11.384 11.385 11.386 11.387 11.388

11.389 11.390 11.391 11.392 11.393 11.394

11.395 11.396 11.397 11.398 11.399 11.400

11.401 11.402 11.403 11.404 11.405 11.406

11.407 11.408 11.409 11.410 11.411 11.412

11.413 11.414 11.415 11.416 11.417 11.418

11.419 11.420 11.421 11.422 11.423 11.424

11.425 11.426 11.427 11.428 11.429 11.430

11.431 11.432 11.433 11.434 11.435 11.436

11.437 11.438 11.439 11.440 11.441 11.442

11.46

11.47 11.48 11.49 11.50 11.51 11.52

11.443 11.444 11.445 11.446 11.447 11.448

11.449 11.450 11.451 11.452 11.453 11.454

11.455 11.456 11.457 11.458 11.459 11.460

11.461 11.462 11.463 11.464 11.465 11.466

11.467 11.468 11.469 11.470 11.471 11.472

11.473 11.474 11.475 11.476 11.477 11.478

11.479 11.480 11.481 11.482 11.483 11.484

11.485 11.486 11.487 11.488 11.489 11.490

11.491 11.492 11.493 11.494 11.495 11.496

11.497 11.498 11.499 11.500 11.501 11.502

11.503 11.504 11.505 11.506 11.507 11.508

11.509 11.510 11.511 11.512 11.513 11.514

11.515

11.516 Demographic and Other Baseline Characteristics

TSIDEM03A: Demographic and Baseline Characteristics (Study 54135419TRD2005: FAS [DB] Analysis Set)

Esk 28
(N=41)
Esk 56
(N=40)
Esk 84
(N=41)
Placebo
(N=80)
Total
(N=202)

Age (years)

N
41
40
41
80
202
Mean (SD)
45.9 (9.97)
42.5 (8.36)
41.9 (10.26)
43.3 (11.40)
43.4 (10.35)
Median
46.0
41.5
43.0
42.5
43.0
Range
(20; 64)
(25; 64)
(22; 63)
(23; 64)
(20; 64)

Age category (years), n (%)

N
41
40
41
80
202
20-44
16 (39.0%)
24 (60.0%)
24 (58.5%)
46 (57.5%)
110 (54.5%)
45-64
25 (61.0%)
16 (40.0%)
17 (41.5%)
34 (42.5%)
92 (45.5%)

Sex, n (%)

N
41
40
41
80
202
Male
18 (43.9%)
24 (60.0%)
23 (56.1%)
41 (51.3%)
106 (52.5%)
Female
23 (56.1%)
16 (40.0%)
18 (43.9%)
39 (48.8%)
96 (47.5%)

Baseline weight (kg)

N
41
40
41
80
202
Mean (SD)
68.47 (16.234)
69.66 (18.756)
66.64 (14.383)
68.40 (13.437)
68.31 (15.290)
Median
65.30
68.35
65.50
66.45
66.15
Range
(39.4; 123.0)
(39.3; 128.4)
(35.8; 95.4)
(43.2; 108.1)
(35.8; 128.4)

Baseline height (cm)

N
41
40
41
80
202
Mean (SD)
162.36 (9.245)
168.38 (7.584)
166.56 (8.991)
165.47 (8.920)
165.64 (8.911)
Median
164.40
169.20
167.70
164.60
166.65
Range
(143.2; 180.0)

(153.5; 181.0)
(145.0; 182.0)
(145.0; 193.0)
(143.2; 193.0)

Baseline BMI (kg/m2)

N
41
40
41
80
202
Mean (SD)
25.81 (4.733)
24.37 (5.388)
23.86 (3.949)
25.01 (4.729)
24.81 (4.735)
Median
24.80
23.80
24.00
24.70
24.25
Range
(17.4; 38.0)
(16.6; 39.5)
(14.1; 31.8)
(16.8; 40.9)
(14.1; 40.9)

BMI category (kg/m2), n (%)

N
41
40
41
80

202
Underweight<18.5
2 (4.9%)
5 (12.5%)
3 (7.3%)
2 (2.5%)
12 (5.9%)
Normal 18.5-<25
19 (46.3%)
19 (47.5%)
24 (58.5%)
40 (50.0%)
102 (50.5%)
Overweight 25-<30
11 (26.8%)
10 (25.0%)
10 (24.4%)
24 (30.0%)
55 (27.2%)
Obese 30-<40
9 (22.0%)
6 (15.0%)
4 (9.8%)
13 (16.3%)
32 (15.8%)
Morbidly obese >=40
0
0
0
1 (1.3%)
1 (0.5%)

Employment status, n (%) (a)

N
41
40
41
80
202
Any type of employment
26 (63.4%)
22 (55.0%)
25 (61.0%)
40 (50.0%)
113 (55.9%)
Any type of unemployment
15 (36.6%)
17 (42.5%)
14 (34.1%)
30 (37.5%)

76 (37.6%)
Other
0
1 (2.5%)
2 (4.9%)
10 (12.5%)
13 (6.4%)

Hypertension status, n (%) (b)

N
41
40
41
80
202
Yes
5 (12.2%)
11 (27.5%)
9 (22.0%)
10 (12.5%)
35 (17.3%)
No
36 (87.8%)
29 (72.5%)
32 (78.0%)
70 (87.5%)
167 (82.7%)

Class of oral antidepressant, n (%)

N
41
40
41
80
202
SNRI

10 (24.4%)
11 (27.5%)
8 (19.5%)
21 (26.3%)
50 (24.8%)
SSRI
28 (68.3%)
28 (70.0%)
28 (68.3%)
53 (66.3%)
137 (67.8%)
Mirtazapine
3 (7.3%)
1 (2.5%)
5 (12.2%)
6 (7.5%)
15 (7.4%)

Oral antidepressant, n (%)

N
41
40
41
80
202
Duloxetine
1 (2.4%)
4 (10.0%)
4 (9.8%)
11 (13.8%)
20 (9.9%)
Venlafaxine XR
9 (22.0%)
7 (17.5%)
4 (9.8%)
10 (12.5%)
30 (14.9%)
Escitalopram
18 (43.9%)
11 (27.5%)
17 (41.5%)
25 (31.3%)
71 (35.1%)
Sertraline
8 (19.5%)
11 (27.5%)
10 (24.4%)
23 (28.8%)
52 (25.7%)
Paroxetine CR

2 (4.9%)
6 (15.0%)
1 (2.4%)
5 (6.3%)
14 (6.9%)
Mirtazapine
3 (7.3%)
1 (2.5%)
5 (12.2%)
6 (7.5%)
15 (7.4%)

Education level, n (%)

N
41
40
41
80
202
Did not complete secondary
school or less than High
School
0
0
0
0
0
Some secondary or high
school education
3 (7.3%)
4 (10.0%)
1 (2.4%)
3 (3.8%)
11 (5.4%)
High School or secondary
school degree complete
20 (48.8%)
14 (35.0%)
12 (29.3%)
25 (31.3%)
71 (35.1%)
Associate's or technical degree
complete
9 (22.0%)
9 (22.5%)
12 (29.3%)
18 (22.5%)
48 (23.8%)
College or baccalaureate
degree complete

9 (22.0%)
12 (30.0%)
16 (39.0%)
32 (40.0%)
69 (34.2%)
Doctoral or post graduate
education
0
1 (2.5%)
0
2 (2.5%)
3 (1.5%)

Key: BMI=body mass index.

(a) Any type of employment includes: any category containing “Employed,” Sheltered Work, Housewife or Dependent Husband, and Student; any type of unemployment includes, any category containing “Unemployed”; Other includes, Retired and No Information Available.

(b) Hypertension status =Yes if SBP \geq 140mmHg and/or DBP \geq 90mmHg at least one timepoint before DB Induction Phase. Hypertension status =No if SBP<140mmHg and DBP<90mmHg at all timepoints before DB Induction Phase.

[TSIDEM03A.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSIDEM03A.SAS] 10FEB2020, 04:39

11.517 Measurements of Treatment Compliance

Please fill or remove the Subsection in the Template

11.518 Efficacy Results and Tabulations of Individual Subject Data

Please fill or remove the Subsection in the Template

11.519 Pharmacokinetic, Pharmacodynamic, and Pharmacogenomic/ Pharmacogenetic Results

Please fill or remove the Subsection in the Template

11.520 Efficacy {and Clinical Pharmacology} Conclusions

Please fill or remove the Subsection in the Template

12 Safety Evaluation

12.1 Extent of Exposure

Please fill or remove the Subsection in the Template

12.2 Adverse Events

12.2.1	
12.2.2	12.2.3
12.2.4	12.2.5
12.2.6	12.2.7
12.2.8	12.2.9
12.2.10	12.2.11
12.2.12	12.2.13
12.2.14	12.2.15
12.2.16	12.2.17
12.2.18	12.2.19
12.2.20	12.2.21
12.2.22	12.2.23

12.2.1

12.2.2

12.2.3

12.2.24

12.2.25

12.2.26

12.2.27

12.2.28

12.2.29

12.2.30

12.2.31

12.2.32

12.2.33

12.2.34

12.2.35

12.2.36

12.2.37

12.2.38

12.2.39

12.2.40

12.2.41

12.2.42

12.2.43

12.2.44

12.2.45

12.2.46

12.2.47

12.2.48

12.2.49

12.2.50

12.2.51

12.2.52

12.2.53

12.2.1

12.2.2

12.2.3

12.2.54

12.2.55

12.2.56

12.2.57

12.2.58

12.2.59

12.2.60

12.2.61

12.2.62

12.2.63

12.2.64

12.2.65

12.2.66

12.2.67

12.2.68

12.2.69

12.2.70

12.2.71

12.2.72

12.2.73

12.2.74

12.2.75

12.2.76

12.2.77

12.2.78

12.2.79

12.2.80

12.2.1

12.2.2

12.2.3

12.2.81

12.2.82

12.2.83

12.2.84

12.2.85

12.2.86

12.2.87

12.2.88

12.2.89

12.2.90

12.2.91

12.2.92

12.2.93

12.2.94

12.2.95

12.2.96

12.2.97

12.2.98

12.2.99

12.2.100

12.2.101

12.2.102

12.2.103

12.2.104

12.2.105

12.2.106

12.2.107

12.2.108

12.2.109

12.2.110

12.2.111

12.2.112

12.2.113

12.2.114

12.2.115

12.2.116

12.2.117

12.2.118

12.2.119

12.2.120

12.2.121

12.2.122

12.2.123

12.2.124

12.2.125

12.2.126

12.2.127

12.2.128

12.2.129

12.2.130

12.2.131

12.2.132

12.2.133

12.2.134

12.2.135

12.2.136

12.2.137

12.2.138

12.2.139

12.2.140

12.2.141

12.2.142

12.2.143

12.2.144

12.2.145

12.2.146

12.2.147

12.2.148

12.2.149

12.2.150

12.2.151

12.2.152

12.2.153

12.2.154

12.2.155

12.2.156

12.2.157

12.2.158

12.2.159

12.2.160

12.2.161

12.2.162

12.2.163

12.2.164

12.2.165

12.2.166

12.2.167

12.2.168

12.2.169

12.2.170

12.2.171

12.2.172

12.2.173

12.2.174

TSFAE02F: Adverse Events by MedDRA System Organ Class and Preferred Term; Open-label Follow-up Phase (Study 54135419TRD2005: FU [OL] Analysis Set)

Flex Esk
(N=48)

Total no. subjects with adverse events
10 (20.8%)

General disorders and administration site conditions

2 (4.2%)
Face oedema
1 (2.1%)
Feeling abnormal
1 (2.1%)

Infections and infestations

2 (4.2%)
Nasopharyngitis
2 (4.2%)
Sinusitis
1 (2.1%)

Musculoskeletal and connective tissue disorders

2 (4.2%)
Neck pain
1 (2.1%)
Pain in extremity
1 (2.1%)

Nervous system disorders

2 (4.2%)
Akathisia
1 (2.1%)
Dizziness postural
1 (2.1%)
Hypoaesthesia
1 (2.1%)

Cardiac disorders

1 (2.1%)
Atrioventricular block second degree
1 (2.1%)

Injury, poisoning and procedural complications

1 (2.1%)
Confusion
1 (2.1%)
Skin abrasion
1 (2.1%)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

1 (2.1%)

Uterine leiomyoma

1 (2.1%)

Psychiatric disorders

1 (2.1%)

Nightmare

1 (2.1%)

Respiratory, thoracic and mediastinal disorders

1 (2.1%)

Choking sensation

1 (2.1%)

Skin and subcutaneous tissue disorders

1 (2.1%)

Eczema

1 (2.1%)

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events.

Note: Adverse events are coded using MedDRA version 22.0.

[TSFAE02F.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSFAE02F.SAS] 10FEB2020, 04:17

TSFAE01B: Overall Summary of Adverse Events; Double-blind Follow-up Phase (Study 54135419TRD2005: FU [DB] Analysis Set)

Esk 28

(N=27)

Esk 56

(N=29)

Esk 84

(N=23)

Total Esk

(N=79)

Placebo

(N=53)

Total

(N=132)

AEs

3 (11.1%)

7 (24.1%)

5 (21.7%)

15 (19.0%)

13 (24.5%)

28 (21.2%)

AEs possibly related to intranasal drug

(a)

2 (7.4%)

0

1 (4.3%)

3 (3.8%)

2 (3.8%)

5 (3.8%)

AEs possibly related to oral antidepressant (a)

0
0
0
0

1 (1.9%)

1 (0.8%)

AEs leading to death

0
0
0
0
0
0
0

1 or more serious AEs

0
0

1 (4.3%)

1 (1.3%)

2 (3.8%)

3 (2.3%)

AEs leading to oral antidepressant withdrawn (b)

0
0
0
0
0
0
0

(a) Drug relationships of possible, probable, and very likely are included in this category.

(b) An adverse event that started in the double-blind induction phase and resulted in discontinuation in the follow-up phase is counted as treatment-emergent in the double-blind induction phase.

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events.

Note: Adverse events are coded using MedDRA version 22.0.

[TSFAE01B.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSFAE01B.SAS] 10FEB2020, 04:16

TSFAE01C: Overall Summary of Adverse Events; Post Treatment Phase (Study 54135419TRD2005: Safety [responders] Analysis Set)

Esk 28

(N=13)

Esk 56

(N=11)

Esk 84

(N=17)

Total Esk

(N=41)

Placebo

(N=27)

Total

(N=68)

AEs

6 (46.2%)

4 (36.4%)

6 (35.3%)

16 (39.0%)

11 (40.7%)

27 (39.7%)

AEs possibly related to intranasal drug(a)

2 (15.4%)

0

1 (5.9%)

3 (7.3%)

0

3 (4.4%)

AEs possibly related to oral

antidepressant (a)

1 (7.7%)

0

0

1 (2.4%)

0

1 (1.5%)

AEs leading to death

0

0

0

0

0

0

0

1 or more serious AEs

0

0

0

0

0

0

0

AEs leading to oral antidepressant

withdrawn (b)

0

0

0

0

0

0

(a) Drug relationships of possible, probable, and very likely are included in this category.

(b) An adverse event that started in the double-blind induction phase and resulted in discontinuation in the post treatment phase is counted as treatment-emergent in the double-blind induction phase.

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events.

Note: Adverse events are coded using MedDRA version 22.0.

[TSFAE01C.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSFAE01C.SAS] 10FEB2020, 04:17

TSFAE01D: Overall Summary of Adverse Events; Within 4-Week After Double-blind Induction Phase (Study 54135419TRD2005: Safety [DB] Analysis Set)

Esk 28

(N=41)

Esk 56

(N=41)

Esk 84

(N=40)

Total Esk

(N=122)

Placebo

(N=80)

Total

(N=202)

AEs	
7 (17.1%)	
10 (24.4%)	
10 (25.0%)	
27 (22.1%)	
20 (25.0%)	
47 (23.3%)	
AEs possibly related to intranasal drug	
(a)	
4 (9.8%)	
0	
2 (5.0%)	
6 (4.9%)	
2 (2.5%)	
8 (4.0%)	
AEs possibly related to oral	
antidepressant (a)	
1 (2.4%)	
0	
0	
1 (0.8%)	
1 (1.3%)	
2 (1.0%)	
AEs leading to death	
0	
0	
0	
0	
0	
0	
0	
1 or more serious AEs	
0	
0	
0	
0	
2 (2.5%)	
2 (1.0%)	
AEs leading to oral antidepressant	
withdrawn (b)	
0	
0	
0	
0	
0	
0	
0	

(a) Drug relationships of possible, probable, and very likely are included in this category.

(b) An adverse event that started in the double-blind induction phase and resulted in discontinuation in a following phase is counted as treatment-emergent in the double-blind induction phase.

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events.

Note: Adverse events are coded using MedDRA version 22.0.

[TSFAE01D.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSFAE01D.SAS] 10FEB2020, 04:17

12.2.235

12.2.236 12.2.237 12.2.238 12.2.239 12.2.240 12.2.241

12.2.242 12.2.243 12.2.244 12.2.245 12.2.246 12.2.247

12.2.248 12.2.249 12.2.250 12.2.251 12.2.252 12.2.253

12.2.254 12.2.255 12.2.256 12.2.257 12.2.258 12.2.259

12.2.260 12.2.261 12.2.262 12.2.263 12.2.264 12.2.265

12.2.266 12.2.267 12.2.268 12.2.269 12.2.270 12.2.271

12.2.272 12.2.273 12.2.274 12.2.275 12.2.276 12.2.277

12.2.278 12.2.279 12.2.280 12.2.281 12.2.282 12.2.283

12.2.284

12.2.235

12.2.236 12.2.237 12.2.238 12.2.239 12.2.240 12.2.241

12.2.285

12.2.286 12.2.287

12.2.288 12.2.289

12.2.290 12.2.291

12.2.292 12.2.293

12.2.294 12.2.295

12.2.296 12.2.297

12.2.298 12.2.299

12.2.300 12.2.301

12.2.302

12.2.303

12.2.304 12.2.305 12.2.306 12.2.307 12.2.308 12.2.309

12.2.310 12.2.311 12.2.312 12.2.313 12.2.314 12.2.315

12.2.316 12.2.317 12.2.318 12.2.319 12.2.320 12.2.321

12.2.322 12.2.323 12.2.324 12.2.325 12.2.326 12.2.327

12.2.328 12.2.329 12.2.330 12.2.331 12.2.332 12.2.333

TSFAE01A: Overall Summary of Treatment-emergent Adverse Events; Double-blind Induction Phase (Study 54135419TRD2005: Safety [DB] Analysis Set)

Esk 28	
(N=41)	
Esk 56	
(N=41)	
Esk 84	
(N=40)	
Total Esk	
(N=122)	
Placebo	
(N=80)	
TEAEs	
33 (80.5%)	
39 (95.1%)	
39 (97.5%)	
111(91.0)	
51 (63.8%)	
TEAEs possibly related to intranasal drug (a)	
30 (73.2%)	
37 (90.2%)	
37 (92.5%)	
104(85.2)	
27 (33.8%)	
TEAEs possibly related to oral antidepressant (a)	
1 (2.4%)	
3 (7.3%)	
3 (7.5%)	
7 (5.7%)	
5 (6.3%)	
TEAEs leading to death	
0	
0	
0	
0	
0	
1 or more serious TEAEs	
1 (2.4%)	
0	
1 (2.5%)	
2 (1.6%)	
1 (1.3%)	
TEAEs leading to intranasal drug withdrawn (b)	
1 (2.4%)	
5 (12.2%)	
1 (2.5%)	
7 (5.7%)	
3 (3.8%)	
TEAEs leading to oral antidepressant withdrawn (b)	
0	
0	
0	
0	
0	

(a) Drug relationships of possible, probable, and very likely are included in this category.

(b) An adverse event that started in the double-blind induction phase and resulted in discontinuation in a following phase is counted as treatment-emergent in the double-blind induction phase.

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events.

Note: Adverse events are coded using MedDRA version 22.0.

[TSFAE01A.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSFAE01A.SAS] 10FEB2020, 04:16

TSFAE01E: Overall Summary of Treatment-emergent Adverse Events; Open-label Induction Phase (Study 54135419TRD2005: Safety [OL] Analysis Set)

Flex Esk
(N=48)
TEAEs
48 (100.0%)
TEAEs possibly related to intranasal drug (a)
48 (100.0%)
TEAEs possibly related to oral antidepressant (a)
2 (4.2%)
TEAEs leading to death
0
1 or more serious TEAEs
1 (2.1%)
TEAEs leading to intranasal drug withdrawn (b)
1 (2.1%)
TEAEs leading to oral antidepressant withdrawn (b)
0

(a) Drug relationships of possible, probable, and very likely are included in this category.

(b) An adverse event that started in the open-label induction phase and resulted in discontinuation in the open-label follow-up phase is counted as treatment-emergent in the open-label induction phase.

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events.

Note: Adverse events are coded using MedDRA version 22.0.

[TSFAE01E.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSFAE01E.SAS] 10FEB2020, 04:17

TSFAE02A: Treatment-emergent Adverse Events by MedDRA System Organ Class and Preferred Term; Double-blind Induction Phase (Study 54135419TRD2005: Safety [DB] Analysis Set)

Esk 28
(N=41)
Esk 56
(N=41)
Esk 84
(N=40)
Total Esk
(N=122)
Placebo
(N=80)

Total no. subjects with TEAEs
33 (80.5%)
39 (95.1%)
39 (97.5%)
111 (91.0%)
51 (63.8%)

Nervous system disorders

23 (56.1%)

33 (80.5%)

31 (77.5%)

87 (71.3%)

24 (30.0%)

Dizziness

11 (26.8%)

18 (43.9%)

15 (37.5%)

44 (36.1%)

5 (6.3%)

Somnolence

10 (24.4%)

13 (31.7%)

11 (27.5%)

34 (27.9%)

14 (17.5%)

Hypoaesthesia

7 (17.1%)

8 (19.5%)

5 (12.5%)

20 (16.4%)

4 (5.0%)

Headache

6 (14.6%)

5 (12.2%)

4 (10.0%)

15 (12.3%)

3 (3.8%)

Sedation

1 (2.4%)

4 (9.8%)

5 (12.5%)

10 (8.2%)

0

Dizziness postural

0

3 (7.3%)

2 (5.0%)

5 (4.1%)

0

Mental impairment

3 (7.3%)

2 (4.9%)

0

5 (4.1%)

0

Tremor

1 (2.4%)

2 (4.9%)

1 (2.5%)

4 (3.3%)

3 (3.8%)

Depressed level of consciousness

1 (2.4%)


1 (2.4%)

1 (2.5%)

3 (2.5%)
0
Disturbance in attention
0
2 (4.9%)
1 (2.5%)
3 (2.5%)
0
Dysarthria
1 (2.4%)
0
2 (5.0%)
3 (2.5%)
0
Dysgeusia
1 (2.4%)
2 (4.9%)
0
3 (2.5%)
1 (1.3%)
Hypotonia
0
0
3 (7.5%)
3 (2.5%)
0
Dyslalia
0
0
2 (5.0%)
2 (1.6%)
0
Hyperaesthesia
0
1 (2.4%)
1 (2.5%)
2 (1.6%)
0
Sensory disturbance
0
2 (4.9%)
0
2 (1.6%)
0
Slow speech
0
2 (4.9%)
0
2 (1.6%)
0
Akathisia
0
0
1 (2.5%)
1 (0.8%)
1 (1.3%)
Altered state of consciousness
0
1 (2.4%)
0
1 (0.8%)
1 (1.3%)

Amnesia
0
1 (2.4%)
0
1 (0.8%)
1 (1.3%)
Bradykinesia
0
1 (2.4%)
0
1 (0.8%)
0
Dizziness exertional
0
1 (2.4%)
0
1 (0.8%)
0
Facial paralysis
0
0
1 (2.5%)
1 (0.8%)
0
Lethargy
0
0
1 (2.5%)
1 (0.8%)
0
Migraine
0
1 (2.4%)
0
1 (0.8%)
0
Poor quality sleep
1 (2.4%)
0
0
1 (0.8%)
0
Presyncope
0
1 (2.4%)
0
1 (0.8%)
0
Psychiatric disorders
18 (43.9%)
20 (48.8%)
26 (65.0%)
64 (52.5%)
10 (12.5%)
Dissociation


14 (34.1%)
10 (24.4%)
22 (55.0%)
46 (37.7%)
7 (8.8%)
Euphoric mood
0
4 (9.8%)
3 (7.5%)
7 (5.7%)
0
Hallucination, visual
1 (2.4%)
2 (4.9%)
1 (2.5%)
4 (3.3%)
0
Anxiety
0
2 (4.9%)
1 (2.5%)
3 (2.5%)
1 (1.3%)
Daydreaming
2 (4.9%)
1 (2.4%)
0
3 (2.5%)
1 (1.3%)
Hallucination
0
1 (2.4%)
2 (5.0%)
3 (2.5%)
0
Hallucination, auditory
1 (2.4%)
1 (2.4%)
1 (2.5%)
3 (2.5%)
0
Suicidal ideation
0
1 (2.4%)
2 (5.0%)
3 (2.5%)
2 (2.5%)
Time perception altered
1 (2.4%)
2 (4.9%)
0
3 (2.5%)
0
Affect lability
0
2 (4.9%)
0
2 (1.6%)
0
Confusional state
0
1 (2.4%)




0
Panic attack
1 (2.4%)
0
0
1 (0.8%)
0
Somatic hallucination
1 (2.4%)
0
0
1 (0.8%)
0

Investigations
14 (34.1%)
20 (48.8%)
23 (57.5%)
57 (46.7%)
15 (18.8%)
Blood pressure increased
12 (29.3%)
19 (46.3%)
19 (47.5%)
50 (41.0%)
8 (10.0%)
Respiratory rate increased
2 (4.9%)
1 (2.4%)
1 (2.5%)
4 (3.3%)
0
Blood pressure diastolic increased
0
0
2 (5.0%)
2 (1.6%)
2 (2.5%)
Blood pressure systolic increased
0
2 (4.9%)
0
2 (1.6%)
2 (2.5%)
Respiratory rate decreased
0
0
2 (5.0%)
2 (1.6%)
0
Weight decreased
2 (4.9%)
0
0
2 (1.6%)
1 (1.3%)

Weight increased	0
	0
	2 (5.0%)
	2 (1.6%)
	0
Blood creatine phosphokinase increased	0
	1 (2.4%)
	0
	1 (0.8%)
	0
Body temperature increased	1 (2.4%)
	0
	0
	1 (0.8%)
	0
Electrocardiogram QT prolonged	0
	1 (2.4%)
	0
	1 (0.8%)
	0
Glucose urine present	1 (2.4%)
	0
	0
	1 (0.8%)
	1 (1.3%)
Liver function test increased	0
	1 (2.4%)
	0
	1 (0.8%)
	0
White blood cells urine positive	0
	1 (2.4%)
	0
	1 (0.8%)
	0
Alanine aminotransferase increased	0
	0
	0
	0
	1 (1.3%)
Aspartate aminotransferase increased	0
	0
	0
	0
	0
	1 (1.3%)
Blood phosphorus decreased	0
	0
	0
	0
	0
	1 (1.3%)
Blood potassium increased	0




Gastrointestinal disorders



1 (2.5%)
2 (1.6%)
1 (1.3%)
Abdominal discomfort
1 (2.4%)
0
0
1 (0.8%)
1 (1.3%)
Dental caries
0
1 (2.4%)
0
1 (0.8%)
0
Salivary hypersecretion
0
1 (2.4%)
0
1 (0.8%)
0
Abdominal distension
0
0
0
0
1 (1.3%)
Abdominal pain
0
0
0
0
0
3 (3.8%)
Gastrointestinal disorder
0
0
0
0
1 (1.3%)
Glossodynia
0
0
0
0
1 (1.3%)

General disorders and administration site conditions
6 (14.6%)
16 (39.0%)
11 (27.5%)
33 (27.0%)
7 (8.8%)
Asthenia
2 (4.9%)
7 (17.1%)



0
Pyrexia
0
1 (2.4%)
0
1 (0.8%)
1 (1.3%)

Ear and labyrinth disorders

5 (12.2%)
9 (22.0%)
10 (25.0%)
24 (19.7%)
2 (2.5%)
Vertigo
4 (9.8%)
7 (17.1%)
8 (20.0%)
19 (15.6%)
1 (1.3%)

Hyperacusis

0
1 (2.4%)
2 (5.0%)
3 (2.5%)

Tinnitus

1 (2.4%)
0
2 (5.0%)
3 (2.5%)

Ear discomfort


1 (2.4%)
1 (2.4%)
0
2 (1.6%)
0

Ear canal stenosis

0
0
0
0
1 (1.3%)

Eye disorders

5 (12.2%)
8 (19.5%)
4 (10.0%)



Asthenopia

0

0

0

0

1 (1.3%)

Respiratory, thoracic and mediastinal disorders

2 (4.9%)

6 (14.6%)

6 (15.0%)

14 (11.5%)

8 (10.0%)

Hyperventilation

1 (2.4%)

2 (4.9%)

0

3 (2.5%)

1 (1.3%)

Oropharyngeal pain

0

1 (2.4%)

2 (5.0%)

3 (2.5%)

2 (2.5%)

Nasal discomfort

0

1 (2.4%)

1 (2.5%)

2 (1.6%)

1 (1.3%)

Rhinalgia

1 (2.4%)

0

1 (2.5%)

2 (1.6%)

1 (1.3%)

Bradypnoea

0

0

1 (2.5%)

1 (0.8%)

0

Choking

0

1 (2.4%)

0

1 (0.8%)

0

Epistaxis

0

0

1 (2.5%)

1 (0.8%)

1 (1.3%)

Hiccups

0
1 (2.4%)
0
1 (0.8%)
0
Intranasal hypoaesthesia
1 (2.4%)
0
0
1 (0.8%)
0
Pharyngeal hypoaesthesia
1 (2.4%)
0
0
1 (0.8%)
0
Respiratory distress
0
0
1 (2.5%)
1 (0.8%)
0
Dyspnoea
0
0
0
0
1 (1.3%)
Rhinorrhoea
0
0
0
0
1 (1.3%)

Musculoskeletal and connective tissue disorders
1 (2.4%)
5 (12.2%)
2 (5.0%)
8 (6.6%)
6 (7.5%)
Muscular weakness
0
2 (4.9%)
2 (5.0%)
4 (3.3%)
0
Musculoskeletal stiffness
0
2 (4.9%)
0
2 (1.6%)
2 (2.5%)
Arthralgia

0
1 (2.4%)
0
1 (0.8%)
0
Back pain
0
1 (2.4%)
0
1 (0.8%)
2 (2.5%)
Pain in jaw
1 (2.4%)
0
0
1 (0.8%)
0
Myalgia
0
0
0
0
1 (1.3%)
Neck pain
0
0
0
0
1 (1.3%)

Cardiac disorders
2 (4.9%)
3 (7.3%)
2 (5.0%)
7 (5.7%)
1 (1.3%)
Palpitations
1 (2.4%)
2 (4.9%)
2 (5.0%)
5 (4.1%)
1 (1.3%)
Ventricular extrasystoles
1 (2.4%)
1 (2.4%)
0
2 (1.6%)
0

Infections and infestations

3 (7.3%)

1 (2.4%)

3 (7.5%)

7 (5.7%)

6 (7.5%)

Cystitis

1 (2.4%)

0

1 (2.5%)

2 (1.6%)

1 (1.3%)

Nasopharyngitis

1 (2.4%)

0

1 (2.5%)

2 (1.6%)

3 (3.8%)

Gastroenteritis

1 (2.4%)

0

0

1 (0.8%)

0

Otitis externa

0

1 (2.4%)

0

1 (0.8%)

1 (1.3%)

Pharyngitis

0

0

1 (2.5%)

1 (0.8%)

0

Upper respiratory tract infection

0

0

0

0

1 (1.3%)

Skin and subcutaneous tissue disorders

1 (2.4%)

5 (12.2%)

1 (2.5%)

7 (5.7%)

4 (5.0%)

Eczema

1 (2.4%)

1 (2.4%)

1 (2.5%)

3 (2.5%)

1 (1.3%)

Hyperhidrosis

0
2 (4.9%)
0
2 (1.6%)
0
Pruritus
0
1 (2.4%)
0
1 (0.8%)
2 (2.5%)
Skin fissures
0
1 (2.4%)
0
1 (0.8%)
0
Erythema
0
0
0
0
1 (1.3%)

Vascular disorders
0
4 (9.8%)
2 (5.0%)
6 (4.9%)
2 (2.5%)
Flushing
0
1 (2.4%)
1 (2.5%)
2 (1.6%)
0
Hot flush
0
1 (2.4%)
1 (2.5%)
2 (1.6%)
2 (2.5%)
Hypertension
0
1 (2.4%)
0
1 (0.8%)
0
Peripheral coldness
0
1 (2.4%)
0
1 (0.8%)
0

Renal and urinary disorders

0

3 (7.3%)

1 (2.5%)

4 (3.3%)

1 (1.3%)

Bladder discomfort

0

0

1 (2.5%)

1 (0.8%)

0

Calculus urinary

0

1 (2.4%)

0

1 (0.8%)

0

Micturition urgency

0

1 (2.4%)

0

1 (0.8%)

0

Pollakiuria

0

1 (2.4%)

0

1 (0.8%)

0

Dysuria

0

0

0

0

1 (1.3%)

Hepatobiliary disorders

2 (4.9%)

1 (2.4%)

0

3 (2.5%)

1 (1.3%)

Alcoholic liver disease

0

1 (2.4%)

0

1 (0.8%)

0

Hepatic function abnormal

1 (2.4%)
0
0
1 (0.8%)
1 (1.3%)
Non-alcoholic steatohepatitis
1 (2.4%)
0
0
1 (0.8%)
0

Injury, poisoning and procedural complications
1 (2.4%)
2 (4.9%)
0
3 (2.5%)
1 (1.3%)
Fracture
1 (2.4%)
0
0
1 (0.8%)
0
Heat illness
0
1 (2.4%)
0
1 (0.8%)
1 (1.3%)
Scratch
0
1 (2.4%)
0
1 (0.8%)
0

Reproductive system and breast disorders
1 (2.4%)
1 (2.4%)
0
2 (1.6%)
1 (1.3%)
Genital haemorrhage
0
1 (2.4%)
0
1 (0.8%)
0

Vaginal haemorrhage

1 (2.4%)

0

0

1 (0.8%)

0

Metrorrhagia

0

0

0

0

1 (1.3%)

Immune system disorders

0

0

1 (2.5%)

1 (0.8%)

0

Seasonal allergy

0

0

1 (2.5%)

1 (0.8%)

0

Metabolism and nutrition disorders

0

0

1 (2.5%)

1 (0.8%)

2 (2.5%)

Decreased appetite

0

0

1 (2.5%)

1 (0.8%)

1 (1.3%)

Dehydration

0

0

0

0

1 (1.3%)

Blood and lymphatic system disorders

0
0
0
0
1 (1.3%)
Anaemia
0
0
0
0
1 (1.3%)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)

0
0
0
0
1 (1.3%)
Uterine leiomyoma
0
0
0
0
1 (1.3%)

Note: Incidence is based on the number of subjects experiencing at least one adverse event, not the number of events.

Note: Adverse events are coded using MedDRA version 22.0.

[TSFAE02A.RTF] [JNJ-54135419\TRD2005\DBR_CSR\RE_CSR\PROD\TSFAE02A.SAS] 10FEB2020, 04:17

12.2.1572 Analysis of Adverse Events

12.2.1572.1 Severity

Please fill or remove the Subsection in the Template

12.2.1572.2 Relationship to Study Drug

Please fill or remove the Subsection in the Template

12.2.1573 Immunization Tolerance

Please fill or remove the Subsection in the Template

12.3 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events

12.3.1 Deaths

Please fill or remove the Subsection in the Template

12.3.2 Serious Adverse Events

Please fill or remove the Subsection in the Template

12.3.3 Adverse Events Leading to Dose Modification

Please fill or remove the Subsection in the Template

12.3.4 Adverse Events Resulting in Treatment Discontinuation

Please fill or remove the Subsection in the Template

12.4 Clinical Laboratory Evaluation

12.4.1 Listing of Individual Laboratory Measurements by Subject and Each Abnormal Laboratory Value

Please fill or remove the Subsection in the Template

12.4.2 Evaluation of Each Laboratory Parameter

Please fill or remove the Subsection in the Template

12.5 Vital Signs, Physical Findings and Other Observations Related to Safety

Please fill or remove the Subsection in the Template

12.6 Concomitant Medication Use

Please fill or remove the Subsection in the Template

12.7 Safety Conclusions

Please fill or remove the Subsection in the Template

13 Discussion and Overall Conclusions

Please fill the section

14 Tables, Listings and Figures/Graphs

15 References

- American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th ed; 2000.
- Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. *Biol Psychiatry*. 2010 Feb 1;67(3):255-62.
- Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. *BMC Psychiatry*. 2010;10:2-7.
- Barnes TRE. A rating scale for drug-induced akathisia. *Br J Psychiatry* 1989;154:672-676.
- Barnes TRE. The Barnes Akathisia Rating Scale – Revisited. *J Psychopharmacology* 2003; 17(4): 365-370.
- Buysse, Daniel J.; Reynolds, Charles F.; Monk, Timothy H.; Berman, Susan R.; Kupfer, David J. (May 1989). "The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research". *Psychiatry Research* 28 (2): 193–213. .doi:10.1016/0165-1781(89)90047-4.
- Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. *J Clin Psychopharmacology*. 2004;24:192-208.
- First 2015 MB, Williams JBW, Karg RS, Spitzer RL: Structured Clinical Interview for DSM -5 Disorders, Clinical Trials Version (SCID-5-CT). Arlington, VA, American Psychiatric Association, 2015.
- Guy W. EDCEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ No ADM 76-338). Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:534-537.
- Inada T, Inagaki A. Psychotropic dose equivalence in Japan. *Psychiatry Clin Neurosci*. 2015 Aug;69(8):440-7.
- Kay SR, Opler LA, Fisbein A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY: Multi-Health Systems, 1994.
- Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. *Annu Rev Med* 2001;52:503-517.
- Keefe RSE, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. *Neuropsychopharmacology*. 2006;31:2033-2046.
- Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. *Neurotherapeutics*. 2009;6:78-85.
- Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. *Schizophr Bull*. 2010;36:94-103.
- Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. *Prog Brain Res*. 2008;172:199-212.
- Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry*. 2004;161(suppl 2):1-56.

- Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second -generation versus first- generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet*. 2009;373:31-41.
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med*. 2005;353:1209-1223.
- Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Philips D, Xu, J, Kalali, AH, Schweizer E, Pikalov A, Loebel A. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study. *Am J Psychiatry*. 2011;168:957-967.
- Minzenberg, et al. Chapter 10: Schizophrenia. In: Hales RE, Yudofsky SC, Gabbard GO, eds. *The American Psychiatric Publishing Textbook of Psychiatry*. 5th edition. Arlington, VA: American Psychiatric Publishing, Inc; 2008.
- Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalization in recent-onset schizophrenia. *BMC Psychiatry*. 2008;8:32-37.
- Munetz MR, Benjamin S. How to examine subjects using the Abnormal Involuntary Movement Scale. *Hospital and Community Psychiatry* 1988; 39: 1172-1177.
- Munro J, Osborne S, Dearden L, Pascoe K, Gauthier A, Price M. Hospital treatment and management in relapse of schizophrenia in the UK: associated costs. *The Psychiatrist*. 2011;35:95-100.
- Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. *CNS Drugs*. 2009;23:649-659.
- Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, Loebel A. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2009;70:829-836.
- Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. *Arch Gen Psychiatry*. 2002;59:115-123.
- National Institute of Mental Health (NIMH). Schizophrenia. <http://www.nimh.nih.gov/health/publications/schizophrenia/schizophrenia-booklet-2009.pdf>. Accessed October 20, 2010.
- Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. *J Clin Psychiatry*. 2007;68 (suppl 4):8-13.
- Opler LA, Kay SSR, Lindenmayer JP, Fiszbein A. Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS). Toronto: Multi-Health Systems, 1992.
- Patel KH, Hlavinka PF. Schizophrenia: Optimal therapy with second-generation antipsychotic agents. *Pharmacy Today*. 2007;13:71-84.
- Pearlson GD. Neurobiology of schizophrenia. *Ann Neurol*. 2000;48:556-566.
- Perkins DO, Stroup TS, Lieberman JA. Psychotic disorders measures. In *Handbook of Psychiatric Measures*. Washington, D.C.: American Psychiatric Association, 2000 p. 485-513.
- Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. *Am J Psychiatry*. 2007 Jul; 164 (7):1035-1043.
- Schultz SK, Andreasen NC. Schizophrenia. *Lancet*. 1999;353:1425-1430.
- Siddiqui O, Hung HM, O'Neil R. MMRM versus LOCF: A comprehensive comparison based on

simulation study and 25 NDA datasets. *Journal of Biopharmaceutical Statistics*, 2009; 19: 227-246.

Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. *Acta Psychiatrica Scandinavica*, Suppl 1970; 212S: 11-19.

Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. *Schizophrenia Res*. 2008;100:20-38.

Webber MA, Marder SR. Better pharmacotherapy for schizophrenia: what does the future hold? *Current Psychiatry Reports*. 2008;10:352-358.

Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the Montgomery-Asberg Depression Rating Scale (SIGMA). *Br J Psych*. 2008; 192: 5-58.

Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. *Psychol Med*. 2006;36:1535-1540.

16 Appendices

16.1 Study Information

16.1.1 Protocol and Protocol Amendments

Please fill or remove the Subsection in the Template

16.1.2 Case Report Form

Please fill or remove the Subsection in the Template

16.1.3 Ethics Committees and Subject Information

Please fill or remove the Subsection in the Template

16.1.4 Regulatory Approval

Please fill or remove the Subsection in the Template

16.1.5 Investigators and Study Personnel

Please fill or remove the Subsection in the Template

16.1.6 Sponsor and Investigator Signatures

Please fill or remove the Subsection in the Template

16.1.7 Randomization Code

Please fill or remove the Subsection in the Template

16.1.8 Study Drugs

Please fill or remove the Subsection in the Template

16.1.9 Audit Certificate

Please fill or remove the Subsection in the Template

16.1.10 Statistical Analysis Plan

Please fill or remove the Subsection in the Template

16.1.11 Laboratory Quality Assurance

Please fill or remove the Subsection in the Template

16.1.12 Publications Based on the Study

Please fill or remove the Subsection in the Template

16.1.13 Publications Referenced in the Report

Please fill or remove the Subsection in the Template

16.2 Patient Data Listings

Please fill or remove the Subsection in the Template

16.3 Case Report Forms

16.3.1 CRFs for Deaths, Other Serious Adverse Events and Withdrawals for AE

Please fill or remove the Subsection in the Template

16.3.2 Other CRFs Submitted

Please fill or remove the Subsection in the Template